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Inflammatory processes mark all stages of atherogenesis. One of the key regulators of 
inflammation is the transcription factor nuclear factor kappa B (Nf-kb). Nf-kb is the general 
name for a whole family of dimeric transcription factors. One can distinguish between a 
classical and an alternative pathway with Rela/p50 (Nf-kb1) and Relb/p52 (Nf-kb2) 
representing the terminal transcription factors, respectively. Classical Nf-kb1 signaling has 
been associated with atherosclerotic lesion development many times, mainly because of its 
regulation of many pro-inflammatory proteins with an established role in atherogenesis. 
Recent studies provided evidence of crosstalk between classical Nf-kb1 and alternative Nf-
kb2 signaling, implicating a potential role for Nf-kb2 in atherogenesis. The aim of the present 
study was to investigate the influence of Nf-kb2 on atherosclerotic lesion development in a 
knockout mouse model. 
 
Nfkb2 knockout (Nfkb2-/-) mice were generated on two different atherosclerosis sensible 
backgrounds, the Apoe- and Ldlr- deficient background. Quantification of atherosclerotic 
lesion development showed, that Nfkb2-/- mice developed significantly more atherosclerosis 
at the brachiocephalic artery than wild type controls, indicating a protective effect of Nf-kb2 
on atherogenesis. Further expression analyses in bone marrow-derived macrophages 
(BMDM) revealed highly significant upregulation of matrix metalloproteinase 9 (Mmp9) in 
Nfkb2-/- mice. Overexpression of Mmp9 was associated with enhanced macrophage 
migration across extracellular matrix in vitro and an inflammatory plaque phenotype with 
advanced, macrophage-rich lesions. Accordingly, increased Mmp9 expression in Nfkb2-/- 
macrophages might have contributed to enhanced lesion development in these mice. 
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1 Introduction 
Atherosclerosis is a fibroproliferative disease in the wall of large and medium-sized arteries. 
It is characterized by the accumulation of lipids which triggers an inflammatory response 
leading to cell migration and proliferation. Together with enhanced extracellular matrix (ECM) 
production these changes determine gradual narrowing of the vessel´s diameter and limited 
blood flow in downstream organs. Plaque rupture and thrombosis can occur eventually, 
causing acute vascular obliteration, e.g. in the coronary arteries and brain vessels, which 
manifests as myocardial infarction and stroke. 
 
In western societies atherosclerosis is still the leading cause of death and loss of productive 
life years, accounting for 16.7 million deaths each year (Dahlof 2010). In Germany 
cardiovascular diseases were responsible for more than 40% (352.689) of all deaths in 2010 
(Statistisches Bundesamt, Wiesbaden 2011). Comprehensive epidemiological studies have 
revealed several important environmental and genetic risk factors associated with 
atherosclerosis (Lusis 2000). Factors with a strong genetic component are elevated levels of 
low density lipoproteins (Ldl), elevated blood pressure, diabetes and obesity (Assmann, 
Cullen et al. 1999), reduced levels of high density lipoproteins (Hdl) (Gordon and Rifkind 
1989), elevated lipoprotein (a) Lp(a) (Kronenberg, Kronenberg et al. 1999), family history 
(Goldbourt and Neufeld 1986), depression (Glassman and Shapiro 1998), gender (Nathan 
and Chaudhuri 1997), and systemic inflammation (Kugiyama, Ota et al. 1999). Known 
environmental risks are smoking, high-fat-diet, and lack of exercise (Assmann, Cullen et al. 
1999).  
 
To date, the pathogenesis of atherosclerotic lesion formation is still not completely 
understood, which is why new therapy approaches are missing. Especially the impact of the 
immune system has been a topic of intensive research over the last years. Different authors 
have proposed that inflammation plays a key role and transduces the effect of many known 
risk factors (Hansson, Libby et al. 2002; Getz 2005; Hansson 2005). 
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1.1 Pathogenesis of atherosclerotic lesion formation 
1.1.1 Lesion initiation and progression 
Atherosclerotic lesions begin as fatty streaks (Figure 1) underlying the endothelium of large 
arteries. In response to irritative stimuli (dyslipidemia, hypertension) endothelial cells are 
activated and express adhesion molecules like vascular cell adhesion molecule 1 (Vcam-1) 
and intercellular adhesion molecule 1 (Icam-1). Consequently, leukocytes (mostly 
monocytes) adhere to endothelial cells and migrate in the tunica intima, driven amongst 
others by monocyte chemotactic protein 1 (Mcp-1). Parallel changes in endothelial 
permeability and the composition of the extracellular matrix beneath the endothelium 
promote the entry and retention of apolipoprotein b (Apob)-containing Ldl particles in the 
artery wall. Apob is responsible for interactions between Ldl and matrix-proteoglycans such 
as collagen and elastin (Boren, Olin et al. 1998). In addition to Ldl other Apob-containing 
particles, namely Lp(a) and very low density lipoprotein (Vldl)-remnants, can accumulate in 
the intima and promote atherogenesis.  
 
The trapped Ldl undergoes oxidative modifications caused by the attack of 
myeloperoxidases and lipoxygenases, or by reactive oxygen species (ROS) (Cyrus, Witztum 
et al. 1999). Such modifications initially lead to minimally oxidized Ldl (oxLdl) with pro- 
inflammatory activity. OxLdl stimulates the overlying endothelial cells to produce a number of 
pro-inflammatory molecules, including adhesion molecules and growth factors such as 
macrophage colony-stimulating factor (m-Csf). 
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Figure 1. Scheme of atherosclerotic lesion formation (Libby, Ridker et al. 2011). 
 
Within the intima, monocytes differentiate into macrophages and take up lipids. Ldl must be 
further modified (“highly oxidized”) before it can be taken up sufficiently by macrophages to 
form lipid-laden foam cells. Foam cells are characterized by an elevated expression of 
scavenger receptors (essential for oxLdl-uptake) and enhanced production of inflammatory 
cytokines like tumor necrosis factor alpha (Tnf-) and interleukin 6 (Il-6).  
 
The transition from the relatively simple fatty streak to the more complex fibrous lesion 
(Figure 1) involves the migration of smooth muscle cells (SMC) from the media in the intima, 
which proliferate together with resident SMCs. Several risk factors, including elevated levels 
of homocysteine and angiotensin II, promote this progress (Gerhard and Duell 1999). Apart 
from SMC-accumulation, fibrous plaques are characterized by a growing mass of extra-
cellular lipid, mostly cholesterol and its ester and SMC-derived extracellular matrix forming 
the fibrous cap. When atherosclerotic lesions enlarge, plaque macrophages and SMCs 
eventually die by apoptosis and necrosis releasing intracellular lipid. The lipid accumulates in 
the central region of the plaque forming the necrotic core (Lusis 2000). 
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1.1.2 Advanced lesions and thrombosis 
Acute cardiovascular events like stroke and myocardial infarction are generally thought to 
result from plaque rupture and thrombosis (Lee and Libby 1997). The probability of 
developing thrombus-mediated cardiovascular events depends principally on the composition 
and vulnerability of the plaque rather than on the severity of the stenosis. Vulnerable plaques 
naturally have a relatively high concentration of lipid-filled macrophages within the shoulder 
region, large necrotic cores, an increased numbers of inflammatory cells, and a relatively 
thin, instable fibrous cap (Davies, Richardson et al. 1993; Lee and Libby 1997). The stability 
of the fibrous cap depends on the balance of ECM-production and degradation by 
proteinases, particularly matrix metalloproteinases (Mmps). Mmps are mainly secreted by 
macrophages and can degrade various ECM components at physiological pH-value. The 
plaques´ shoulders and regions of foam cell accumulation display locally increased 
expression of Mmps and are therefore prone to rupture (Galis, Sukhova et al. 1994). Plaque 
rupture exposes plaque lipids and tissue factor to blood components, initiating the 
coagulation cascade, platelet adherence, and thrombosis. 
1.2 Immune function in atherogenesis 
For many years it was assumed that atherosclerosis was merely the result of passive 
accumulation of cholesterol in the vessel wall. Today the picture is more complex, with 
atherosclerosis being thought of as a chronic inflammatory disease (Ross 1999). The 
following paragraph provides a short overview of inflammatory pathways in atherogenesis 
and the role of innate and adaptive immunity. 
 
As described above, atherosclerosis begins with the recruitment of inflammatory cells (mainly 
monocytes which differentiate into macrophages) to the intima. During the initiation of lesion 
formation, innate immune responses such as expression of scavenger receptors by foam 
cells and toll-like receptor (Tlr)-signaling in endothelial cells and macrophages play a major 
role (Figure 2) (Greaves and Gordon 2009). A central protein in Tlr-signaling is represented 
by myeloid differentiation primary response gene (88) (Myd88), which was shown to promote 
atherosclerosis in apolipoprotein E (Apoe)-deficient mice (Michelsen, Wong et al. 2004). 
Myd88 is used by all Tlrs (except Tlr-3) to activate the transcription factor nuclear factor 
kappa B (Nf-kb). Nf-kb induces gene expression of target genes such as pro-inflammatory 
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cytokines, chemokines, adhesion molecules, and proteases (Figure 2), initiating the chronic 
inflammatory response. 
 
 
Figure 2. Activation of innate immune responses in the atheroma (Hansson and Hermansson 
2011). 
 
Parallel to macrophages T-cells are recruited into the intima. Within atherosclerotic lesions, 
T-cells are activated and produce pro-atherogenic mediators which contribute to lesion 
growth and disease aggravation (Hansson, Robertson et al. 2006). This is mainly driven by 
the T helper type 1 (TH1) response with its signature cytokine interferon gamma (Ifn-). Ifn- 
increases protease and chemokine secretion, upregulates adhesion molecules, induces 
proinflammatory cytokines and activates macrophages and endothelial cells (Hansson, 
Robertson et al. 2006). Animal experiments revealed that mice deficient in Ifn- or its 
receptor exhibit less lesion development than control mice (Gupta, Pablo et al. 1997), while 
infusion of exogenous Ifn- was shown to promote atherosclerosis (Whitman, Ravisankar et 
al. 2000). 
 
Another subset of T-cells present in atherosclerotic lesions are forkhead box P3 (Foxp3+) 
regulatory T (Treg)-cells (de Boer, van der Meer et al. 2007). Treg cells produce Il-10 and 
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transforming growth factor beta (Tgf-), two cytokines that have been shown to have 
profound athero-protective effects in mouse models (Ait-Oufella, Salomon et al. 2006). 
 
Although not numerically prominent in the plaque, B-cells accumulate and organize in the 
perivascular tissue surrounding atherosclerotic arteries. They produce circulating 
immunoglobulin M (IgM) antibodies which are able to block the uptake of oxLdl by scavenger 
receptors. Interestingly, these antibodies do not only recognize oxLdl but also antigens in the 
cell wall of Staphylococcus aureus (Binder, Horkko et al. 2003). Further studies need to 
determine if molecular mimicry between pathogens and Ldl could possibly lead to 
atheroprotective immunity. 
 
The clarification of the molecular mechanisms in atherosclerosis shows, that the cellular 
interactions are basically comparable to those in other chronic inflammatory diseases. As 
demonstrated above (Figure 2) the transcription factor Nf-kb represents a central signaling 
component in the inflammatory process of atheroma formation. The fallowing paragraph 
provides a short summary of the Nf-kb transcription factor family and its role in health and 
disease. 
1.3 The Nf-kb signaling system 
Nf-kb is the general name for a whole family of dimeric transcription factors. It was first 
discovered in the lab of Nobel Prize laureate David Baltimore via its interaction with an 11-
base pair sequence in the immunoglobulin light-chain enhancer in B cells (Sen and Baltimore 
1986). Nf-kb is found in almost all animal cell types and is involved in the cellular response to 
stimuli such as stress, cytokines, free radicals, UV irradiation, oxidized Ldl, and bacterial or 
viral antigens (Gilmore 1999). As Nf-kb family members are present in the cytoplasm of 
inactive cells, they do not require new protein synthesis to activate transcription. This allows 
Nf-kb to be one of the first responders in innate and adaptive immunity (“rapid acting 
transcription factors”). Over 400 target genes of Nf-kb have already been identified 
(http://www.bu.edu/Nfkb/gene-resources/target-genes) and incorrect regulation of Nf-kb has 
been linked to autoimmune diseases, cancer, septic shock, cardiac hypertrophy, cystic 
fibrosis, and atherosclerosis. (Sha, Liou et al. 1995; Weih, Carrasco et al. 1995; Franzoso, 
Carlson et al. 1997; Baldwin 2001; Bonizzi and Karin 2004; de Winther, Kanters et al. 2005; 
Pikarsky and Ben-Neriah 2006). 
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1.3.1 Nf-kb family members 
The mammalian Nf-kb complex consists of five members: p105/p50 (Nf-kb1), p100/p52 (Nf-
kb2), p65 (Rela), Relb and c-Rel (Table 1) (Figure 3). All family members share a nucleic 
acid (N)-terminal structural homology with the retroviral oncoprotein v-Rel. This Rel-
homology-domain (RHD) is highly conserved, 300 amino acid long, and responsible for DNA-
binding, dimerization, and nuclear translocation (Figure 3) (Li and Verma 2002). Based on 
sequences carboxy (C)-terminal to the RHD, Nf-kb family members can be classified into Nf-
kb (Class I) and Rel (Class II)-proteins (Table 1) (Sen and Baltimore 1986). 
 
Table 1. Nf-kb/Rel Protein. 
Class Gene Protein Aliases Precursor 
I 
Nfkb1 Nf-kb1 p50 p105 
Nfkb2 Nf-kb2 p52 p100 
II 
Rela Rela p65  
Relb Relb   
Rel c-Rel   
 
Members of class I (the Nfkb proteins p105/p50 and p100/p52) have long C-terminal 
domains that contain multiple copies of ankyrin repeats, which act to inhibit these molecules. 
Members of class II (the Rel proteins Rela, Relb and c-Rel) contain C-terminal non-
homologous transcription activation domains (TDs) which are essential to activate 
transcription (Figure 3) (Li and Verma 2002). 
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Figure 3. Simplified scheme of mammalian Nf-kb family members and Ikb proteins (modified 
according to Li and Verma 2002). Class I and Class II proteins have a N-terminal Rel-homology 
domain (RHD), which contains the dimerization, nuclear-localization (N), and DNA-binding domains. 
Class II proteins also have carboxy (C)-terminal non-homologous transactivation domains (TDs). 
Inhibitor of kappa b (Ikb) family members and Bcl-3 are characterized by the presence of many 
ankyrin repeats. P105 and p100 contain RHDs at the amino terminus and ankyrin repeats at the 
carboxy terminus. Proteolytic processing (PP) of p105 and p100 generates the p50 and p52 Nf-kb 
proteins, respectively. 
 
Rel/Nf-kb transcription factors bind to 9-10 base pair DNA sites (called kB sites) as dimers. 
All vertebrate Rel proteins can form homodimers or heterodimers, except for Relb, which can 
only form heterodimers (Li and Verma 2002). Given the fact that the Rel proteins exclusively 
contain TDs, the Nf-kb proteins p50 and p52 can only activate transcription by dimerisation 
with Rela, Relb, or c-Rel (Siebenlist, Franzoso et al. 1994). Another opportunity for p50/p52 
to behave as transcriptional activators is by interaction with Bcl-3. Bcl-3 is an inhibitor of 
kappa B (Ikb)-related protein with ankyrin repeat motifs and nuclear localization. It interacts 
specifically with p50 and p52 homodimers and can induce the expression of Nf-kb regulated 
genes (Nolan, Fujita et al. 1993; Li and Verma 2002). The availability of specific dimers is 
regulated during cell differentiation and organ development and determines the cell’s 
responsiveness to inflammatory or developmental signals (Basak, Shih et al. 2008). 
 
The activity of Nf-kb is primarily regulated by interaction with members of a family of ankyrin 
repeat domain (ARD)-containing inhibitors called inhibitor of kappa B (Ikb) proteins (Figure 
3), which interact with the RHD of Rel/Nf-kb- proteins. Comparable to the Rel/Nf-kb proteins, 
there are several Ikb proteins, which have different affinities for individual Rel/Nf-kb 
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complexes, and are expressed in a tissue-specific manner. The Ikb proteins include, at least, 
p105, p100, Ikb, Ikb, Ikbe, and Bcl-3 (Gilmore 2006). 
1.3.2 Nf-kb pathways 
Among the Nf-kb-family one can distinguish between two different pathways: the classical Nf-
kb1 signaling pathway with Rela/p50 as predominant terminal transcription factor and the 
alternative Nf-kb2 signaling pathway represented by Relb/p52 dimers (Figure 4). Both p50 
and p52 are generated from larger precursor proteins, namely p105 for the classical and 
p100 for the alternative pathway (Table 1). 
1.3.2.1 Classical Nf-kb1 signaling 
In resting cells, Nf-kb dimers are sequestered in the cytoplasm as latent complexes through 
binding to Ikb-proteins. Accordingly, the major pathway leading to Nf-kb activation, called 
classical pathway, is based on inducible Ikb degradation allowing Nf-kb dimers to accumulate 
in the nucleus and activate transcription (Figure 4). 
The degradation of Ikb molecules is generally mediated through their phosphorylation by the 
Ikb kinase (Ikk), a trimeric complex composed of two catalytic subunits, Ikkα and Ikkβ, and a 
regulatory subunit, Ikkγ (also named Nfkb essential modulator or NEMO) (Figure 4) (Xiao, 
Rabson et al. 2006). In the classical Nf-kb1 pathway, activation of the Ikk complex leads to 
phosphorylation of Ikb by Ikk which targets Ikb for ubiquitination and degradation by the 
26S proteasome. The unmasked Nf-kb complex is then able to enter the nucleus and 
activate gene expression. The most frequently forming dimer in most cell types is the 
Rela/p50 heterodimer (Li and Verma 2002), which is why the term “Nf-kb” commonly refers 
to Rela/p50 complexes. 
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Figure 4. Classical and alternative Nf-kb signaling pathway (modified according to Weih and 
Caamano 2003). 
 
One of the target genes of classical Nf-kb1 signaling is the inhibitor protein Ikb, which 
functions as a negative feedback regulator of Nf-kb1 activation (Li and Verma 2002). Thus, 
the activation of the classical Nf-kb1 pathway is naturally a transient process, lasting from 30 
– 60 minutes in most cells. Importantly, the Nf-kb precursors p105 and p100 also contain an 
Ikb-like C-terminal portion (Figure 3) and can function as Nf-kb inhibitors. Accordingly, the 
processing of p105 and p100, which selectively degrades their C-terminal portions, works as 
an alternative mechanism for Nf-kb activation. Whereas the processing of p105 is 
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constitutive, p100 processing is tightly controlled and highly inducible (Xiao, Rabson et al. 
2006). The Nf-kb activation mediated by p100 processing is thus termed alternative Nf-kb2 
pathway. 
1.3.2.2 Alternative Nf-kb2 signaling 
Since its discovery about 20 years ago (Neri, Chang et al. 1991), the alternative Nf-kb 
pathway has become an area of intense research. The distinctive feature of alternative Nf-
kb2 signaling is its dependence on p100 processing, which is tightly regulated and depends 
on targeted activation by a specific set of receptors (Figure 4) (Munroe and Bishop 2004). 
Thus, in most cell types Nf-kb2 is mainly represented by cytoplasmatic p100 due to a lack of 
active processing of this precursor (Betts and Nabel 1996). To date, the best characterized 
alternative Nf-kb2 receptors are a subset of tumor necrosis factor receptor (Tnfr) superfamily 
members, including B-cell activating factor belonging to Tnf family receptor (Baffr) (Claudio, 
Brown et al. 2002), CD40 (Coope, Atkinson et al. 2002), lymphotoxin  receptor (Ltr) 
(Dejardin, Droin et al. 2002), receptor activator for nuclear factor kappa B (Rank) (Novack, 
Yin et al. 2003), Tnfr2 (Rauert, Wicovsky et al. 2010), and Fn14 (Saitoh, Nakayama et al. 
2003) (Figure 4). 
A central signaling component of the alternative Nf-kb pathway is the Nf-kb-inducing kinase 
(Nik), which integrates signals from the Tnf-receptors and activates the downstream Ikk 
(Xiao, Harhaj et al. 2001). Ikk then forms homodimers and phosphorylates the C-terminal 
region of p100. The phosphorylation of p100 leads to partial proteolysis of the Ikb-like C-
terminal portion, releasing active p52-complexes (preferentially Relb/p52) into the nucleus 
(Figure 4). 
1.3.3 The alternative Nf-kb2 pathway in health and disease 
The processing of p100 regulates important biological functions such as survival and 
maturation of B-cells, development of peripheral lymphoid organs, dendritic cell activation, 
thymic deletion of autoimmune T cells, and bone metabolism (Dejardin 2006). Deregulated 
activation of the alternative Nf-kb pathway is associated with severe disorders including 
autoimmunity, inflammation, osteoporosis, and most notably lymphoid malignancies. Several 
studies have documented that truncations in the COOH-terminal region of the Nfkb2 gene 
are associated with the development of cutaneous T-cell lymphomas, chronic lymphocytic 
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leukemias, and multiple myelomas (Migliazza, Lombardi et al. 1994; Thakur, Lin et al. 1994; 
Chang, Zhang et al. 1995) The rearranged Nfkb2 gene products lack the C-terminal 
processing inhibitory domain (PID) of p100 which then undergoes constitutive processing 
(Xiao, Harhaj et al. 2001). 
The pathological consequence of p100 disruption has also been revealed by a study using 
Nfkb2-knockin mice which suffer from a lack of p100 (by targeted disruption of the COOH- 
terminal ankyrin repeats of Nfkb2) but still contain a functional p52 protein (p100 knockout 
mice). These mice display marked gastric and lymphoid hyperplasia and early postnatal 
lethality (Ishikawa, Carrasco et al. 1997). 
 
To further investigate the function of Nf-kb2, Caamano et al. generated Nfkb2 knockout mice 
in 1998 (Caamano, Rizzo et al. 1998). Nfkb2-deficient (Nfkb2-/-) mice showed a lack of 
follicular dendritic cell network in secondary lymphoid organs (spleen, lymph nodes, Peyer´s 
patches) which led to an altered architecture characterized by diffuse irregular B cell areas 
and the absence of discrete perifollicular marginal and mantle zones as well as loss of 
germinal centres (Caamano, Rizzo et al. 1998; Franzoso, Carlson et al. 1998). Along with 
these structural changes Nfkb2-/- mice suffered from an impaired antibody response and 
thereby immunodeficiency. In detail, proliferation of Nfkb2-deficient B cells was moderately 
reduced in response to lipopolysaccharide and CD40, but maturation and immunoglobulin 
switching were normal. However, challenges with T-cell-dependent or -independent antigens 
revealed that Nfkb2-/- mice presented an insufficient production of antigen- specific antibodies 
(Caamano, Rizzo et al. 1998). 
These findings indicate an important role of Nf-kb2 in the maintenance of peripheral B cell 
population, humoral response, and normal spleen architecture (Caamano, Rizzo et al. 1998).  
1.3.4 Nf-kb target genes 
Since its discovery about 20 years ago, more than 400 target genes of Nf-kb family members 
have been identified. A detailed summary of Nf-kb target genes is given on the internet: 
http://www.bu.edu/Nfkb/gene-resources/target-genes. 
 
In 2006 Schreiber et al. was able to provide information about how the different Nf-kb 
subunits act coordinately to regulate gene expression. Using genome-scale location analysis, 
he was able to identify targets of all five Nf-kb proteins. Thus, Nf-kb target genes can be 
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divided into two sets: those that are bound before cellular stimulation and those that are only 
bound after cellular stimulation. In unstimulated cells, p50 and p52 account for the majority of 
Nf-kb binding activity. After stimulation with lipopolysaccharides (LPS) additional subunits 
especially Rela, c-Rel, and Relb bind to gene promotors. Genes that are bound by multiple 
Nf-kb subunits are most likely to show an increase in gene expression (Schreiber, Jenner et 
al. 2006). 
Specific “kB-binding sites” that are preferentially recognized by Relb/p52 (Nf-kb2) dimers 
were identified by Bonizzi et al. in 2004. They are located in the promoters of organic 
chemokine genes which have been found to be critical for spleen organogenesis and 
maintenance of tissue-microarchitecture (Bonizzi, Bebien et al. 2004). However, regarding 
the fact that Nf-kb2 is present as inhibitory p100 in the cytoplasm of most cells, one can 
assume that many genes are indirectly regulated by Nf-kb2. 
1.4 Nf-kb in atherogenesis 
Evidence supporting a role for the classical Nf-kb1 pathway in atherosclerotic lesion 
development is based mainly on descriptive studies. In 1993 Parhami et al. found that 
oxidized Ldl activates Nf-kb1 in endothelial cells (Parhami, Fang et al. 1993). In 1996, Brand 
and Page were able to demonstrate that activated Nf-kb1 transcription factors can be found 
in human atherosclerotic lesions. Using an antibody specifically recognizing activated 
phospharylated p65, Nf-kb1 activation was shown in SMC, macrophages, and endothelial 
cells, whereas little activated Nf-kb1 was detected in healthy vessels (Brand, Page et al. 
1996). Moreover, hypercholesteremia was shown to induce activated Nf-kb1 in the vessel 
wall in a pig model for atherosclerosis (Wilson, Caplice et al. 2000). Using mice, Hajra et al. 
provided evidence that there was a colocalization of regions prone to develop atherosclerosis 
and increased levels of components of the Nf-kb1 signaling system (Hajra, Evans et al. 
2000). 
 
Further studies revealed that the induction of a variety of inflammatory genes in 
atherosclerotic lesions depends on Nf-kb1 signaling, including Tnf, Il1a, M-csf, Mcp-1, 
Vcam-1, and Icam-1 (Brand, Page et al. 1996; Collins and Cybulsky 2001; de Winther, 
Kanters et al. 2005). Hence, Nf-kb is likely to regulate inflammatory pathways in 
atherosclerotic lesion formation from the initiation of atherosclerosis by modified lipids (oxLdl) 
and attraction of monocytes (Mcp-1) over foam cell formation (m-Csf) to chronic inflammation 
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(Tnf, Il1a). Interestingly, Nf-kb equally drives factors that may protect against atherosclerotic 
lesion development such as Il-10 (de Winther, Kanters et al. 2005), implying that the role of 
Nf-kb in atherogenesis is not strictly pro-inflammatory.  
 
As mentioned above, many different signaling pathways can activate Nf-kb1. Recently, some 
of them have been investigated in atherosclerotic mouse models. Table 2 provides an 
overview of mouse experiments, investigating components of the Nf-kb1 activation cascade 
and their influence on atherogenesis. 
 
Table 2. Mouse experiments investigating components of the Nf-kb activation cascade and 
their influence on atherosclerotic lesion development compared to wild type controls (modified 
according to de Winther 2005). 
Gene Model Lesion area Background Remarks 
Tnf K0 − ↓ Wt, Apoe
-/-
  
Lt K0 ↓ Wt  
Tnfr I K0 ↑ Wt  
Tnfr II K0 − Wt  
Il1 K0 ↓ Apoe
-/-
 Reduced Vcam-1, Mcp-1 
Il1r K0 ↓ Apoe
-/-
  
Il18 K0 ↓ Apoe
-/-
 Stable plaque phenotype 
Tlr4 K0 ↓ Apoe
-/-
  
CD14 K0 − Apoe
-/-
  
Myd88 K0 ↓ Apoe
-/-
 Reduced chemokines 
CD40l K0, BA ↓ Apoe
-/-
, Ldlr
-/-
 Stable plaque phenotype 
Ikk mK0 ↑ Ldlr
-/-
 Increased necrosis 
p50 hK0 ↓ Ldlr
-/-
 Inflammatory phenotype 
Wt: wildtype, K0: knockout, hK0: hematopoietic knockout, mK0: macrophage knockout, BA: blocking 
antibody, ↑ increased lesion area, ↓ decreased lesion area, − no effect on lesion area. 
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As shown in the table, many but not all gene knockouts targeting Nf-kb1 activation, led to 
decreased atherosclerotic lesion development. In regard to Tnfr I (p55), deficiency of this 
receptor even aggravated lesion development in mice (Schreyer, Peschon et al. 1996). 
Likewise macrophage-restricted deletion of Ikk (which targets Ikb for ubiquitination in 
classical Nf-kb1 signaling) increased atherosclerosis in Ldlr-deficient mice (Kanters, 
Pasparakis et al. 2003). The hematopoietic knockout of Nfkb1 in Ldlr-/- mice in fact resulted in 
smaller atherosclerotic lesions, but mice exhibited an inflammatory phenotype (Kanters, 
Gijbels et al. 2004). 
In summary, the role of Nf-kb1 in atherogenesis, appears to be more pro- than anti-
atherogenic, mainly because of its regulation of many proinflammatory genes with an 
established role in atherogenesis. 
 
The role of the alternative Nf-kb2 pathway on atherosclerotic lesion development has not 
been investigated until now. Since its discovery, the relevancy of Nf-kb2 has been linked to 
secondary lymphoid organ development and adaptive immunity because this is where 
activated Relb/p52 transcription factors can primarily be found (Bonizzi and Karin 2004). 
Recent studies however, provided evidence that cytoplasmatic p100 has important regulatory 
functions and that the cellular processes that generate different Nfkb dimers are highly 
connected through multiple cross-regulatory mechanisms (Solan, Miyoshi et al. 2002; Basak, 
Kim et al. 2007; Basak and Hoffmann 2008). This crosstalk implies a potential role for Nf-kb2 
in atherogenesis. To further elucidate these coherences, we decided to investigate the 
influence of Nf-kb2 on atherosclerotic lesion formation in a knockout mouse model. 
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1.5 Aims 
The overall aim of the thesis on hand was to test the hypothesis that the alternative Nf-kb2 
pathway affects atherosclerotic lesion development in a mouse model. Further experiments 
should focus on the detailed mechanisms by which Nf-kb2 might influence atherogenesis, 
especially Nf-kb2 target gene analyses, investigation of plaque composition and functional 
analyses. 
 
The specific aims were: 
 Detection of Nf-kb2 in the vascular system and atherosclerotic lesions. 
 Generation of Nfkb2-/- mice on two atherosclerosis sensible backgrounds, the 
Apoe- and Ldlr- deficient background. 
 Characterization of the Nfkb2-/- phenotype and lipoprotein profile. 
 Histological quantification of atherosclerotic lesion development at the brachio-
cephalic artery and the aortic root of female and male Nfkb2-/- mice on the Ldlr- 
and Apoe- deficient background. 
 Identification of Nf-kb2 specific target genes in macrophages and organs. 
 Verification of target genes on mRNA and protein level. 
 Functional analyses of Nfkb2-/- macrophage properties in vitro. 
 Immunohistological characterization of plaque composition (Plaque phenotyping). 
 Molecular mechanisms of Nfkb2 deficiency. 
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2 Methods 
2.1 Animal experiments 
2.1.1 Mouse strains 
Heterozygous C57BL/6-Nfkb2+/- and C57BL/6-p100 mice, henceforth called Nfkb2+/- 
(Caamano, Rizzo et al. 1998) and p100+/- (Ishikawa, Carrasco et al. 1997) were obtained 
from Prof. Weih (Fritz Libmann Institute, Jena). Nfkb2+/- mice were backcrossed to the Ldlr- 
and Apoe-deficient (Lldr-/-/Apoe-/-) background (the Jackson Laboratory, Bar Harbour, ME) 
(Teupser, Pavlides et al. 2004) to generate C57BL/6-Nfkb2-/-Apoe-/- and C57BL/6-Nfkb2-/- 
Ldlr-/- double knockout mice. 
2.1.2 Breeding and animal husbandry 
Breeding and husbandry of the mice was accomplished in the medical experimental centre of 
the University of Leipzig. All mice were kept under pathogen-free conditions in rooms with 
controlled temperature (22+/-2°C) and a 12:12 light–dark cycle. Water and food was 
provided ad libitum. Mice were weaned at 28 days of age and genotyped by tail tipping.  
 
For atherosclerosis experiments mice were put on a semisynthetic, modified AIN76 diet 
containing 0.02% cholesterol. Mice were sacrificed at 20 weeks of age after 16 weeks of 
feeding (Figure 5) (Teupser, Persky et al. 2003). 
 
 
Figure 5. Study design of atherosclerosis experiments. 
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For atherosclerosis experiments the following mice were generated: 
 
Table 3. Mice for atherosclerosis experiments (20 weeks of age). 
C57BL/6 Apoe
-/-
 Ldlr
-/-
 
Nfkb2 +/+ +/- -/- +/+ -/- 
male 22 21 21 16 17 
female 20 22 20 16 16 
 
Expression analyses in organs and defined vascular segments (Figure 6) was performed in 
male and female Nfkb2+/+ and Nfkb2-/- mice on the Ldlr-/- background at 8 weeks of age. Mice 
have previously been weaned at 28 days of age and fed standard chow for 4 weeks. For 
tissue specific expression analyses the following mice were generated: 
 
Table 4. Mice for tissue specific expression analyses (8 weeks of age). 
C57BL/6 Ldlr
-/-
 
Nfkb2 +/+ -/- 
male 6 6 
female 6 6 
 
P100-/- mice have marked gastric hyperplasia, resulting in early postnatal death (10 weeks of 
age) (Ishikawa, Carrasco et al. 1997). Eight weeks old female p100+/+, p100+/-, and p100-/- 
mice were generated for expression analyses in macrophages and tissues. 
 
Table 5. p100 mice (8 weeks of age). 
C57BL/6  
p100 +/+ +/- -/- 
female 3 3 3 
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2.1.3 Mouse-section 
2.1.3.1 Removal of organs and vessels 
Mice were euthanized by intraperitoneal anesthesia (ketamine-HCL 100 mg/kgBM mixed 
with xylazine-HCL 5 mg/kgBM: 0.2 ml Rompun + 0.6 ml Ketamin). After opening of the 
thorax, blood was collected from the right ventricle with a 1 ml syringe containing EDTA (21.5 
mg/ml). Anticoagulated full-blood was centrifuged for 8 minutes (min) at 8000 U/min. Plasma 
supernatant was collected for clinical chemistry analyses and determination of lipoprotein 
subfractions. The circulatory system was perfused with 10 ml heparinized phosphate 
buffered saline (5000 IU Heparin/1000 ml PBS) through a canula in the left ventricle. 
Removal of organs (liver, spleen, kidney, lung, gut, muscle, thymus, brain) was performed as 
previously described (Teupser, Kretzschmar et al. 2008). Organs were immediately put into 
liquid nitrogen and stored at -80°C. 
 
For atherosclerosis experiments and expression analyses in defined vascular segments, 
special preparation of the brachiocephalic artery (BCA), the heart, and the thoracic aorta was 
performed: 
 
For expression analysis in defined vascular segments, the aortic root (AR), the BCA, the 
aortic arch (AA) and the thoracic aorta (TA) were removed separately by mircodissection and 
stored at -80°C (Figure 6). 
 
 
 
Figure 6. Defined vascular segments for Nfkb2 expression analyses. 
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For quantification of atherosclerotic lesions, the BCA was cut distal to where it branches into 
the right subclavian artery and right carotid artery and then cut at its branching site from the 
aorta, ending up with a Y-shaped piece. Subsequently, the BCA was flushed with PBS, 
embedded in Tissue Tek OCT compound (Sakura), and cryoconserved at 80°C. The removal 
of the heart was performed after sectioning of the aorta ascendens 3 mm above the aortic 
root. The cardiac apex was cut off by transversal dissection parallel to the valvular level. The 
remaining heart was embedded in O.C.T. and cryoconserved at -80°C. (Teupser, Persky et 
al. 2003). 
2.1.3.2 Isolation of murine bone marrow and peritoneal macrophages 
For isolation of murine peritoneal macrophages, 1.5 ml of 3% Brewer thioglycollate medium 
was injected into the peritoneal cavity. The inflammatory response was allowed to proceed 
for 3 days. Peritoneal lavage was performed with 10 ml ice cold DMEM (Dulbecco’s Modified 
Eagle Medium, GIBCO + 4500 mg/L Glucose + GlutaMAX + Pyruvate, Invitrogen). Plastic 
Pasteur pipettes were used for atraumatic collection of the fluid. The collected cell 
suspension was centrifuged for 8 min at 1000 rpm and 4°C. The supernatant was discarded 
and the cell pellet was resuspended in 1 ml DMEM containing 10% FCS and 1% Penicillin-
Streptomycin (Pen-Strep). Cells were counted, seeded on culture plates, and allowed to 
adhere for 3 h at 37°C, 5%CO2. Nonadherent cells were removed by gently washing three 
times with warm PBS. At this time, cells were greater than 90% macrophages (Zhang, 
Goncalves et al. 2008). Adherent cells were investigated in functional assays. 
 
Bone marrow was isolated from both femurs and tibias using 10 ml heparinized PBS 
respectively. After homogenization, the collected cell suspension was drained through a cell 
strainer (40 µm, Nylon, BD) and centrifuged for 8 minutes at 1000 rpm. The supernatant was 
discarded and the cell pellet was resuspended in 1.5 ml DMEM (10% FCS, 1% Pen-Strep) 
and split into 3 tubes à 500 µl. 400 µl FCS and 100 µl DMSO were added. After gradual 
freezing at -80°C for 24 h, cells were transferred into liquid nitrogen as cryopreservation for 
further studies. 
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2.2 Cell culture 
2.2.1 Expression analysis in BMDM 
For genome-wide expression analyses and subsequent validation of target genes, bone 
marrow from Nfkb2+/+, Nfkb2-/-, p100+/+ and p100-/- mice was thawed and macrophages were 
purified by adhesion to cell culture plastic. Macrophages were grown in serum-free medium 
(DMEM, Invitrogen) containing 20% L-cell conditioned medium with 10% FCS and 1% Pen-
Strep. L-cell medium was obtained from L929 mouse fibroblasts according to standard 
protocols. 
Macrophages were cultivated for 14 days, scraped off and plated onto 35-mm dishes 
(Sarstedt) at a cell density of 1x106  cells per well, respectively. Macrophages were grown for 
48 h at 37°C with 5% CO2. After 48 h, medium was changed and cells were stimulated with 
LPS 1 µg/ml (Sigma Aldrich) or LIGHT 100 ng/ml (ALEXIS) or medium control for 8 h. After 
this time the supernatant was removed and cells were lysed with 1 ml of TRIzol reagent 
(Invitrogen) for subsequent RNA isolation. 
2.2.2 Functional analyses in BMDM 
For functional analyses bone marrow from Nfkb2+/+ and Nfkb2-/- mice was immediately 
brought into culture and differentiated into macrophages with L-cell conditioned medium over 
a period of 2 weeks. Mature macrophages were used for cell viability and Matrigel invasion 
assays. 
2.2.3 siRNA experiments in murine RAW cells 
Small interfering ribonucleic acids (siRNA) are short double-stranded RNA molecules (20-25 
base pairs (bp)), which are able to interfere with the expression of specific target genes with 
complementary nucleotide sequences. 
For siRNA experiments, RAW 264.7 cells were grown as described above and plated on 12-
well plates (Sarstedt) at a cell density of 0.2 x 106 cells/well. Cells were transfected with 250 
µl serum free medium (Opti-MEM, Invitrogen) and 250 µl transfection medium consisting of 
siRNA and Lipofectamine  at a ratio of 100 pmol siRNA: 5 µl Lipofectamine. SiRNA against 
Rela (RelasiRNA, Ambion, ID: s72858), Relb (Relb siRNA, Qiagen, ID: 2095456), Nfkb2 
(Nfkb2siRNA, Qiagen, ID: 2048365) and a combination ofRela/Nfkb2 and Relb/Nfkb2 siRNA 
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was used. Three types of control samples were carried along every experiment: 
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) siRNA was used as a positive control 
to monitor efficiency of siRNA delivery into cells. Non-specific scrambled siRNA (SCR) was 
used as a negative control to distinguish sequence specific silencing from non-specific 
effects. Untreated samples (Control 3) were used to determine the baseline level of cell 
viability, phenotype, and target gene level (Table 6). 
 
Table 6. siRNA experiments. 
12-well plate siRNA siRNA Control 1 Control 2 
1 Rela Rela + Nfkb2 Gapdh SCR (Rela) 
2 Relb Relb + Nfkb2 Gapdh SCR (Relb) 
3 Nfkb2 Control 3 Gapdh SCR (Nfkb2) 
 
After Incubation for 4 h at 37°C and 5% CO2, 500 µl DMEM containing 20% FCS, 2% 
pen/strep, and LPS (2 µg/ml) were added. Cells were incubated for 24 h (37°C, 5% CO2) and 
lysed in 750 µl TRIFAST (Peqlab).  
2.3 Histological, histochemical, and immunohistochemical methods 
2.3.1 Quantitative analysis of atherosclerotic lesions 
Quantification of atherosclerosis was performed at the aortic root and the brachiocephalic 
artery as previously described (Paigen, Morrow et al. 1987; Teupser, Pavlides et al. 2004).  
2.3.1.1 Preparation of cryosections of the aortic root and the BCA 
Assessment of atherosclerotic lesions at the aortic root was performed according to a 
method described by Paigen et al. (Paigen, Morrow et al. 1987; Plump, Scott et al. 1994). 
Embedded hearts were cut parallel to the valvular level at 10 µm thickness. Preparation of 
cryosections of the aortic root started when two out of three aortic valves were completely 
visible, 2 sections were preserved per slide (Figure 7). 
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Figure 7. Scheme for preparation of cryosections of the aortic root. 
 
All (a) sections were preserved for oil-red O staining while (b) and (c) sections were used for 
immunohistochemistry. This sequence was repeated twice (1a, b, c – 3a, b, c). Further 
sections were obtained for lesion quantification until only residues remained visible from the 
aortic valve (4a – 6a). The respective four intermediate sections were discarded. All 
cryosections were stored at -80°C for further usage. 
 
To quantify atherosclerosis at the BCA, the OCT-compound-embedded vessels were 
sectioned from distal to proximal in 10 µm slides (Figure 8). 2 sections were preserved per 
slide. At a distance of 200, 400, and 600 µm proximal from the branching point of the BCA 
into the carotid and subclavian arteries the (a) sections were mounted on glass slides and 
used for Oil Red O staining and subsequent lesion quantification. 1b – g , 2b – c, and 3b – c 
sections were cryoconserved for immunohistochemical analyses (Figure 8). 
Aorta
Aortic valve
Left ventricle
Save 2 sections
Discard the respective 4 
intermediate sections
Save 2 sections
(a) Oil Red O, (b-c) IHC
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Figure 8. Scheme for preparation of cryosections of the BCA (Teupser et al. 2003). 
 
2.3.1.2 Histological staining 
For quantitative and qualitative analysis of atherosclerotic lesion formation all (a) sections of 
the BCA and the aortic root were stained with Oil Red O, Light Green, and Hematoxylin. Oil 
Red O is a lysochrome (fat-soluble dye) diazo dye used for the staining of neutral 
triglycerides and lipids on frozen sections. Light Green was used for the staining of collagen 
and elastic fibres and Haematoxylin for the staining of cell nuclei. 
 
The cryosections were fixed in a closed chamber saturated with formalin vapor for 24 h at –
room temperature (RT). Staining was performed with Shandon Varistain Gemini slide stainer. 
 
Staining protocol: 
 
2x  1 min    H2O 
 30 s    Isopropanol 60% 
 18 min   Oil Red O 0.24% 
A. carotis communis und A. subclavia 
A. brachiocephalica 
20 Schnitte à 10µm verwerfen
6 Schnitte à 10µm verwerfen
14 Schnitte à 10µm verwerfen
Start
1a Ölrot O-Färbung
2a Ölrot O-Färbung
3a Ölrot O-Färbung
1b, 1c, 1d, 1e, 1f, 1g 
immunhistochemische Färbung
2b, 2c immunhistochemische Färbung
3b, 3c immunhistochemische Färbung
Discard 20 sections á 10 µm
Starting point
Discard 6 sections á 10 µm
Discard 14 sections á 10 µm
1b, 1c, 1d, 1e, 1f, 1g IHC
1a Oil Red O staining
2b, 2c IHC
2a Oil Red O staining
3b, 3c IHC
3a Oil Red O staining
BCA
A. Carotis communis & A. subclavia
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 30 s    Isopropanol 60% 
2x  1 min   H2O 
 2 min    Haematoxylin Solution Gill No. 3, 2.4% in acetic acid 1% 
 1 min    Bluing Solution 
 1 min    H2O 
 30 s    Light Green 0.25% 
 1 min    H2O 
 
All sections were mounted with warmed (55°C) glycerol gelantine. 
2.3.1.3 Quantification of atherosclerotic lesions 
Quantification of atherosclerotic lesions was performed at Oil Red O-stained sections with 
support of AxioVision.Rel 4.5 software. All (a) sections of the BCA (5x magnification) and the 
aortic root (2.5x magnification) were photographed and digitally saved (AxioVision/SCD950). 
Subsequently, lesions were manually quantified with support of Zeiss-Image-Software KS400 
3.0 (Zeiss). Only intraluminal lesions accounted for quantification neglecting arterial wall 
thickening. 
Atherosclerotic lesions at the BCA were calculated as mean value of lesion quantification of 
the 1a, 2a, and 3a sections. At the aortic root, atherosclerotic lesion size was calculated as 
mean value of five sequenced (a)-sections. Quantification was started when all three valves 
of the aortic root were completely visible (1a – 5a or 2a – 6a) (Teupser, Pavlides et al. 2004). 
2.3.2 Qualitative analysis of atherosclerotic lesions 
Complexity of atherosclerotic lesions was assessed according to the Stary classification, 
adapted to lesions in mice as suggested by Reddick et al. (Reddick, Zhang et al. 1994). 
Lesion analysis was performed at Oil Red O stained sections which allows differentiation 
between intra- and extracellular lipid accumulation. Lesions were categorized from stage 0 to 
3: Sections without atherosclerotic lesions were categorized as stage 0. Early lesions 
consisting predominantly of foam cells (Stary equivalent type I–II) were classified as stage 1. 
Moderate lesions with extracellular lipid deposition or thin fibrous cap development (Stary 
equivalent type III–V) were classified as stage 2, and advanced lesions with complex fibro-
proliferative plaques (Stary equivalent type V–VIII) were classified as stage 3 (Table 7) 
(Mueller, Beutner et al. 2008; Teupser, Kretzschmar et al. 2008). 
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Table 7. Classification of atherosclerotic lesion by a Stary equivalent nomenclature adapted to 
lesions in mice (Mueller et al. 2008). 
 
Early lesions 
(stage 1) 
Moderate lesions 
(stage 2) 
Advanced lesions 
(stage 3) 
Stary-Equivalent Type I – II Type III – V Type V, VII, VIII 
Foam-cell 
characteristics 
Single cells or groups of 
foam cells 
Multiple foam cell 
layers, diffuse, 
Lateral atheroma, 
diffuse 
Lipid accumulation Intracellular Intra-/extracellular Intra-/extracellular 
Cholesterol-crystal None 
May have cholesterol 
crystals 
Cholesterol crystals 
common 
Necrosis None 
Few or no acellular 
areas 
Consistent acellular 
cores 
Fibrosis None 
May have thin fibrous 
cap 
Fibrous cap and 
advanced fibrosis 
 
2.3.2.1 Immunohistochemistry 
Frozen sections of the BCA of female Nfkb2-/-Apoe-/- mice and Nfkb2+/+Apoe-/- controls were 
fixed in ice-cold acetone/methanol (mixture 1:1) for 15 min and washed with PBS (2x). 
Peroxidases were quenched with 3% H2O2 in PBS, 10% methanol (4 min). Sections were 
blocked with 2.5% normal serum (goat serum for Cd68 and rabbit serum for Mmp-9, Il4i1, Nf-
kb2 and -Sma antibodies) for 30 minutes. Primary antibodies were incubated at 4°C 
overnight at dilutions showed in Table 8. Sections were washed twice with PBS and 
incubated with horseradish peroxidase (HRP) -conjugated secondary antibody and 
ImmPRESS-Reagent, respectively, as indicated in Table 8 for 30 minutes at room 
temperature. After washing, peroxidase was visualized by incubation with ImmPACT Nova 
Red (VECTOR Laboratories) and sections were counterstained with hematoxylin. Sections 
were dehydrated and permanently mounted with VectaMount mounting medium (VECTOR 
Laboratories). 
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Table 8. Primary and secondary antibodies used for immunohistochemistry. 
Primary 
Antibody, 
Clone 
Secondary Antibody 
HRP-conjugated 
Host, Isotype Dilution Supplier, Catalogue 
Cd68  Rat, IgG2a 1:10 
AbD Serotec, 
MCA1957 
Mmp-9  Rabbit, IgG 1:100 MILLIPORE, Ab19016 
Nf-kb2  Rabbit, IgG 1:100 
GENTAUR, 
Ab865 
-Sma  Rabbit, IgG 1:200 Abcam, Ab5694 
Il4i1  Rabbit, IgG 1:50 Abcam, Ab18524 
 Anti-rat Goat, IgG 1:50 AbD Serotec, STAR72 
 Anti-rabbit 
ImmPRESS 
Reagent, Ig 
Undiluted 
VECTOR Laboratories, 
MP-7401 
 
2.4 Clinical chemistry and quantification of lipoprotein subfractions 
Plasma parameters (triglycerides, cholesterol, total protein, cholinesterase, alanine 
transaminase, aspartate transaminase and glutamate dehydrogenase) were analysed in an 
automated analyser (Modular PPE, Roche). 
 
Lipoproteins were isolated by sequential ultracentrifugation from 60 µL of plasma at densities 
(d) < 1.006 g/ml (very low-density lipoprotein (Vldl)), 1.006  d  1.063 g/ml (intermediate-
density lipoprotein (Idl) and low-density lipoprotein Ldl)), and d > 1.063 g/ml (high-density 
lipoprotein (Hdl)) in a LE-80K ultracentrifuge (Beckmann) (Teupser, Kretzschmar et al. 2008). 
Therefore 65 µl plasma and 65 µl PBS were mixed and spun in 7 x 20 polyallomere tubes for 
3 h. The upper and the lower phase were separated (tube A and B). 60 µl PBS was added to 
the upper phase (tube A). The lower phase (tube B) was mixed with 60 µl potassium bromide 
(KBr) (d = 1.12g/ml) to yield a final density of 1.063 g/ml. Tubes were centrifuged over night. 
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The upper phase from tube A contained Vldl and remnant particles (d < 1.006 g/ml). The 
lower phase of tube A and the upper phase of tube B contained mostly Ldl (d = 1.006−1.063 
g/ml). The lower phase of tube B contained Hdl (d > 1.063 g/ml). 
 
Cholesterol concentrations of lipoprotein subfractions (Ldl, Vldl, Hdl) were determined with 
an enzymatic colorimetric assay (cholesterol oxidase - phenol - aminophenazone: CHOD-
PAP) (Allain, Poon et al. 1974). Therefore 10 µl of samples or standard solution (20, 60, 100, 
200, 400 mg/dl) were mixed with 200 µl cholesterol reagent (Roche), respectively, and 
incubated for 10 min at RT on an orbital shaker. Subsequent measurement was performed 
with a fluorescence and absorbance reader (Tecan, SpectraFluor) at 500 nm. The intensity 
of the colour produced is directly proportional to the cholesterol concentration and could 
thereby be correlated with the standard curve. 
2.5 Molecular biological methods 
2.5.1 Isolation of genomic DNA 
DNA was isolated from tails of mice by a standardized protocol using tail tip lysis buffer, 
proteinase K, and 100% ethanol for precipitation. Therefore a ~ 0.25 – cm tail-biopsy was 
incubated in a thermomixer (55°C) for 12 h with 500 µl lysis buffer and 50 µl Proteinase K (10 
mg/ml). After centrifugation (5 min, 1500 g), precipitation was performed with 1 ml 100% 
ethanol. The now visible DNA strand was captured with a glass capillary, and dissolved in 
200 – 500 µl 0.1xTE. DNA was stored at - 4°C until further analyses. 
2.5.2 Genotyping 
Genotyping was performed by polymerase chain reaction (PCR). Genotyping of Apoe, Ldlr, 
and Nfkb2 mice was based on detection of the insertion of a promoter sequence or a 
resistance gene by 3-primer analysis. Separation of the PCR product was performed with 
agarose gel electrophoresis as described above. Figure 9 shows a representative gel of 
Nfkb2 genotyping. 
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Figure 9. Molecular weight marker X and 3% agarose gel electrophoresis Nfkb2 knockout PCR. 
 
The following PRC protocols were used: 
 
PCR Apoe knockout: 
DNA      3 µl 
H2O       14.8 µl 
MgCl2 (25 mM)    2 µl 
10 x PCR-Puffer     2.5 µl 
dNTPs (1,25 mM)    2 µl 
IMR180 Primer (100 µM)   0.2 µl 
IMR181 Primer (100 µM )   0.2 µl  
IMR182 Primer (100 µM)   0.2 µl 
Firepol DNA Polymerase I (5 U/µl)  0.1 µl 
Reaction volume    25 µl 
 
PCR conditions: 
3 min  95°C  Initialization 
20 s 95°C  DNA denaturation 
30 s 68°C  Primer annealing 
40 s 72°C  Extension 
7 min 72°C  Final extension 
 
35 cycles 
 M(X)   k0     k0     k0     het    het     het     k0     wt     het     k0 
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PCR Ldlr knockout: 
DNA       5 µl 
H2O       9.33 µl 
MgCl2 (25 mM)    2.5 µl 
10 x PCR-buffer    2.5 µl 
dNTPs (1.25 mM)    2.5 µl 
IMR0092 Primer (100 µM)   1.07 µl 
IMR3349 Primer (100 µM)   0.53 µl 
IMR3350 Primer (100 µM)   1.07 µl 
Firepol® DNA Polymerase I (5 U/µl)  0.5 µl 
Reaction volume    25 µl 
 
PCR conditions: 
3 min  95°C  Initialization 
30 s 95°C  DNA denaturation 
1 min 65°C  Primer annealing 
1 min 72°C  Extension 
2 min 72°C  Final extension 
 
PCR Nfkb2 knockout: 
DNA       2 µl 
H2O      7.46 µl 
MgCl2 (25 mM)    3.2 µl 
10 x PCR buffer     2 µl 
dNTPs (1.25 mM)    3 µl 
Ex 4 Primer (20 pmol/µl)   0.41 µl 
Ex 5 Primer (20 pmol/µl)   0.33 µl 
PGK 1 Primer (20 pmol/µl)   0.41 µl 
Firepol® DNA Polymerase I (5 U/µl)  0.2 µl 
Reaction volume    20 µl 
 
PCR conditions: 
3 min  94°C  Initialization 
35 cycles 
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1 min 94°C  DNA denaturation 
1 min 55°C  Primer annealing 
1 min 72°C  Extension 
7 min 72°C  Final extension 
 
p100-knockin-PCR: 
DNA       2.0 µl 
H2O        12.0 µl 
5 x Green GoTaq PCR buffer   4.0 µl 
dNTPs (10 mM )    0.5 µl 
5927-NFκB2-5946    0.25 µl 
6081-NFκB2-6062    0.25 µl 
20-SV40polyA-39    0.5 µl 
243-SV40polyA-220    0.5 µl 
GoTaq Polymerase (0.5 U Promega) 0.1 µl 
Reaction volume    20 µl 
 
PCR conditions: 
4 min  94°C  Initialization 
45 s 94°C  DNA denaturation 
30 s 57°C  Primer annealing 
40 s 72°C  Extension 
5 min 72°C  Final extension 
 
 
Table 9. Primers used for genotyping. 
Strain Sequence PCR-product 
Apoe
-/-
 
5’ - GCCTAGCCGAGGGAGAGCCG - 3’ 
5 ’- TGTGACTTGGGAGCTCTGCAGC - 3’ 
5’ - GCCGCCCCGACTGCATCT - 3’ 
wildtype: 155 bp 
knockout: 245 bp 
Ldlr
-/-
 
5’ - TGGATGTGGAATGTGTGCGAG - 3’ 
5’ - CCATATGCATCCCCAGTCTT - 3’ 
5’ - GCGATGGATACACTCACTGC - 3’ 
wildtype: 167 bp 
knockout: 350 bp 
33 cycles 
35 cycles 
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Nfkb2
-/-
 
5’ - GCCTGGATGGCATCCCCG - 3’ 
5’ - GTTTGGGCTGTTCCACAA - 3’ 
5’ - CCAGACTGCCTTGGGAAA - 3’ 
wildtype: 230 bp 
knockout: 120 bp 
p100
-/-
 
5´- ATCAATAAACACGAGCGGAG - 3´ 
5´- CAACTAACAGATCCAGGCAC - 3´ 
5’ - ATGAATGGGAGCAGTGGTGG - 3’ 
5’ - GGTGTAAATAGCAAAGCAAGCAAG - 3’ 
wildtype: 155 bp 
knockin: 224bp 
 
2.5.3 RNA extraction 
Isolation of RNA was performed with the guanidinium thiocyanate-phenol-chloroform 
extraction method (Chomczynski and Sacchi 1987). 50 – 100 mg mouse tissue (liver, spleen, 
kidney, lung, gut, muscle, thymus, brain) was homogenized in a Precellys24 homogenizer 
using CK24 ceramic beads and 900 µl TRIzol (Invitrogen). After homogenization 600 µl 
TRizol was added and the homogenized tissue was incubated for 5 min at RT. After 
centrifugation (10 min, 12000 g, 4°C), the supernatant was transferred to a new tube. 300 µl 
chloroform was added, shaken for 15 s and incubated for 2 min at RT. Tubes were 
centrifuged for 20 min at 4°C. The upper aqueous phase was carefully removed and 
precipitated with 750 µl isopropanol (10 min, RT). After centrifugation for 10 min (12000 g, 
4°C), RNA became visible as a white pellet. After removal of the supernatant, the RNA pellet 
was washed with 1 ml 75% ethanol, dried, and dissolved in Diethylpyrocarbonate (DEPC) 
water (55°C, 10 min). RNA was stored at -80°C. 
 
For isolation of RNA from RAW 267.4 cells and bone marrow-derived macrophages, cells 
were lysed in 750 µl TRIzol and 150 µl Chloroform was added. Precipitation was performed 
with 375 µl Isopropanolol. The other steps were performed as described above. 
 
Total RNA from defined vascular segments (AR, BCA, AA, TA, Figure 6).was isolated using 
RNAqueous-Micro (Micro Scale RNA Isolation Kit, Ambion). It contains silica-based filters 
which selectively bind RNA. For RNA isolation vascular segments were lysed in 100 – 300 µl 
lysis buffer, respectively (~10 volumes of lysis solution per mass of tissue). Tissue was 
homogenized in a Precellys24 homogenizer using CK24 ceramic beads. 50 – 150 µl (50 
volume %) of 100% ethanol was added. 150 µl of the lysate/ethanol mixture was loaded onto 
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a Micro Filter Cartridge Assembly and centrifuged for 30 s at room temperature (15000 g). If 
not all of the mixture had passed through the filter the step was repeated. The filter was 
washed with 180 µl Wash Solution 1 and centrifuged for 15 s (RT, 15000g). 180 µl of Wash 
Solution 2/3 was added, and the filter was centrifuged for 15 s (RT, 15000g). The step was 
repeated with a second 180 µl aliquot of Wash Solution 2/3. The flow through was discarded 
from the collection tube and the filter was centrifuged for 1 min at maximum speed to remove 
residual fluid and to dry the filter. The filter was transferred to a Micro Elution Tube. 10 µl 
preheated (75°C) Elution Solution was added and incubated for 1 min at RT. The assembly 
was centrifuged for 1 min to elute the RNA from the filter. The step was repeated with a 
second 10 µl aliquot of preheated Elution Solution. RNA was stored at -80°C. Total amount 
of RNA was quantified using the NanoDrop-System (NanoDrop Technologies). 
 E260    1.0 = 50 µg/ml double-stranded DNA 
 E260    1.0 = 40 µg/ml single-stranded RNA 
The determination of purity was performed with the help of the quotient E
E
280
260
. E260 thereby 
represents the maximum absorption of DNA/RNA whereas E280 refers to those of proteins. 
This quotient should be 1.8 and 2.0 in 1xTE buffer for DNA and RNA, respectively 
(Sambrook and Russell 2006).  
2.5.4 Reverse transcription 
Stable cDNA for PCR amplification was generated by reverse transcription of isolated RNA. 
RNA from bone marrow-derived macrophages, RAW cells, mouse tissue, and vascular 
segments was reversed transcribed into cDNA using Superscript II reverse transcriptase 
(Invitrogen) and random hexamer primers. In detail, 2 µg dissolved RNA was diluted with 
DEPC-H2O to a final volume of 10 µl. 1 µl random hexamer primer was added and probes 
were incubated for 10 min at 68°C. Afterwards 9 µl mastermix was added, which includes: 
 1 µl recombinant RNAsin ribonuclease 
 1 µl dNTPs (10 mM) 
 2 µl DTT (0.1 M) 
 4 µl 5 x first strand buffer 
 1 µl superscript II reverse transcriptase (200 U/µl) 
Methods 
 
34 
 
After incubation for 60 min at 42°C, cDNA of organs, macrophages, and RAW-cells was 
diluted with 1xTE buffer at a ratio of 1:15. cDNA of vessels was diluted with 1xTE Buffer at a 
ratio of 1:5. cDNA samples were stored at -20°C. 
2.5.5 Whole genome mRNA expression analysis 
Whole genome expression analysis was performed in RNA from bone-marrow derived 
macrophages from Nfkb2 -/- mice and wildtype controls on the Ldlr-/- and Apoe-/- background 
(n =  4/4 and n= 4/4, respectively). RNA was labeled and hybridized to Illumina MouseRef-8 
v2.0 Expression Bead Chips and arrays were scanned with an Illumina iScan microarray 
scanner at the Interdisciplinary Center for Clinical Research Leipzig (PD Dr. Knut Krohn, 
Faculty of Medicine, University of Leipzig, Germany). Bead level data pre-processing was 
done in Illumina Genome Studio followed by quantile normalization and background 
reduction according to standard procedures in the software. Fold changes of gene 
expression were calculated using wildtype samples as reference. (Figure 10). 
 
 
Figure 10. Whole genome analysis in macrophages from Nfkb2
+/+
 and Nfkb2
-/-
 mice. 
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2.5.6 Expression analyses with quantitative fluorogenic real-time-PCR (TaqMan) 
Gene expression analyses in BMD macrophages and mouse tissue was performed with 
quantitative fluorogenic real time (RT)-PCR. Sequence-specific DNA probes and primers 
were designed using primer/probe design software (Primer Express 2.0, Applied 
Biosystems). Chosen primer pairs specifically annealed at two sequenced exons of the 
cDNA of candidate genes. The respective probe spanned the exon/exon boundary to avoid 
significant amplification of contaminative genomic DNA. Quantification of DNA targets was 
performed as absolute quantification giving the exact number of target DNA molecules by 
comparison with DNA standards.  
 
Standard curves were generated for each gene by serial dilution of linearized plasmids 
containing the target sequence for the respective qRT-PCR. Therefore, a sequence of more 
than 100 base pairs (bp), containing the target region was amplified using gene specific 
standard primers. Subsequently, the PCR product was inserted into a plasmid vector (pCR 
2.1-TOPO) using the TOPO TA Cloning Kit (Invitrogen) according to the manufacturer’s 
instructions. After successful incorporation, the pCR 2.1-TOPO construct was transformed 
into competent Escheria coli (E. coli) for amplification of the product plasmid. Successfully 
transformed bacteria were selected based on their ampicillin resistance. Besides the 
ampicillin resistance gene the pCR 2.1-TOPO vector contains E.coli lacZas reporter gene 
(Figure 11). After successful incorporation of the PCR product there is a lack of expression of 
beta- galactosidase so that insert-positive bacterial colonies appear white. 
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Figure 11. pCR 2.1-TOPO vector. 
 
Plasmid preparation was performed as minipreparation (FastPlasmid; Eppendorf) or 
maxipreparation (Plasmid Maxi Kit, QIAGEN) according to the manufacturer´s instructions. 
EcoR1 restriction digest was performed to confirm the presence and correct length of the 
insert. To confirm that the PCR product was inserted in the correct orientation we performed 
automatic DNA sequencing (ABI Prism 377, Applied Biosystems). The clone picked as 
standard was linearized by restriction digest and diluted to 1010 single-strand molecules/µl 
with 1xTE buffer. Dilution to the required copy number of the standard curve was performed 
with 1xTE buffer containing 0.06% 5 x First Strand buffer. 
2.5.6.1 Quantification of target genes 
Fluorogenic RT-PCR was performed for quantification of mRNA expression of Nfkb1, Nfkb2, 
Ikb, Rela, Relb, A20, Tnf, Mmp9, Il4i1, and Timp1. In order to minimize errors due to RNA 
quality and correct for sample-sample variations, Beta actin (Ba) was used as housekeeping 
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gene. Sequences of primers and probes are indicated in Table 10. Cloned cDNA fragments 
of the template were used as standards in serial dilutions. Measurement of fluorescence 
intensity was performed with the ABI PRISM 7700 Sequence Detection System (Applied 
Biosystems). Each sample was measured 4 times and average values were used for 
statistical analysis. 
 
Table 10. Primers and TaqMan probes used for quantitative RT-PCR (*: 6-FAM; # TAMRA). 
Gene (ensembl or 
UCSC transcript ID) 
 Sequence 
Ba 
(NM_007393.3) 
5´-primer 
3`-primer 
Probe 
5’- GAGAAGCTGTGCTATGTTGCTC -3’ 
5’- AGGAAGAGGATGCGGCA -3’ 
5’*- AGACTTCGAGCAGGAGATGGCCA -
#
3’ 
A20 
(NM_009397.3) 
5´-primer 
3`-primer 
Probe 
5’- CCAGCACTTTGTACCCCTGGT -3’ 
5’- CAAACCTACCCCGGTCTCTGTT -3’ 
5’*- AGTGGACCTGAACTTCGCGCTGTTCCAC -
#
3’ 
Tnf 
(NM_013693.2) 
5´-primer 
3`-primer 
Probe 
5’- CCACCACGCTCTTCTGTCTACTG -3’ 
5’- TGGGCCATAGAACTGATGAGAGG -3’ 
5’*- CGGTCCCCAAAGGGATGAGAAGTTCCC -
#
3’ 
Nfkb1 
(NM_008689.2) 
5´-primer 
3`-primer 
Probe 
5’- GTACGACAACATCTCCTTGGCTG -3’ 
5’- CAGAGGTGTAGTCCCATCATAGGTG -3’ 
5’*- TGCTTCTGGAGGGTGATGCCCACG -
#
3’ 
Nfkb2 
(NM_019408.3) 
5´-primer 
3`-primer 
Probe 
5’- CAGAAACTTCAGAGGCAGCGTC -3’ 
5’- TCAGCTCCTTGGCCTCCTG -3’ 
5’*- CCTCAGGGCCTTACAGAGGCTGAGCG  -
#
3’ 
Rela 
(NM_009045.4) 
5´-primer 
3`-primer 
Probe 
5’- CCCAGACCGCAGTATCCAT -3’ 
5’- GCTCCAGGTCTCGCTTCTT -3’ 
5’*- CTTCCAGAACCTGGGGATCCAGTGTGTGCCTGAG 
CGATAGACTCCGGTACAGCCG -
#
3’ 
Relb 
(NM_009046.2 
5´-primer 
3`-primer 
Probe 
5’- AAACGAAGGAAAAAGAAACCAGT -3’ 
5’- CGATGGTGGGAGGAACAG -3’ 
5’*- CCACTTCCTGCCTGGCCACAGCTCA -
#
3’ 
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Ikb 
(NM_010907.2) 
5´-primer 
3`-primer 
Probe 
5’- CGAGCCCTGGAAGCAGC -3’ 
5’- CTTCTCTTCGTGGATGATTGCC -3’ 
5’*- CACGGAGGACGGAGACTCGTTCCTGC -
#
3’ 
Mmp9 
(NM_013599.2) 
5´-primer 
3`-primer 
Probe 
5’- TTCTCTGGTGTGCCCTGGAAC -3’ 
5’- AAACTCACACGCCAGAAGAATTT -3’ 
5’*- CACACGACATCTTCCAGTACCAAGACAAAGCC  -
#
3’ 
Il4i1 
(NM_ 010215.3) 
5´-primer 
3`-primer 
Probe 
5’- TGCCTGAGCGATAGACTCC -3’ 
5’- AGGCGCGTTCAGTAGCAG -3’ 
5’*- CTGGGACCTGCTTCCGCGAGCTC -
#
3’ 
Timp1 
(NM_011593.2) 
5´-primer 
3`-primer 
Probe 
5’- CCCAGAACCGCAGTGAAGAG -3’ 
5’- GAAGCTGCAGGCACTGATGTG -3’ 
5’*- TTCTCATCACGGGCCGCCTAAGGAAC -
#
3’ 
 
The following protocol was used for all qRT PCRs: 
 
H2O      4.56 µl 
MgCl2 (25 mM)    2.5 µl 
10 x PCR buffer    1.25 µl 
dNTP (1,25 mM)    1.0 µl 
Forwardprimer (300 nM)   0.19 µl 
Reverseprimer (300 nM)   0.19 µl 
Probe (10 µM)    0.25 µl 
Ampli Taq Gold DNA polymerase (5 U/µl) 0.06 µl 
cDNA/Standard    2.5 µl 
Reaction volume    12.5 µl 
 
PCR conditions: 
10 min  95°C  DNA denaturation 
15 s 95°C  DNA denaturation 
1 min 60°C  Primer annealing and extension 
10 min 60°C  final extension 
40 cycles 
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2.6 Functional analyses 
2.6.1 SDS page zymography 
Zymography is a two-stage technique based on SDS page involving protein separation by 
electrophoresis followed by detection of enzymatic (proteolytic) activity. Zymogram analysis 
is used for detecting and characterizing metalloproteinases, collagenases, and other 
proteases that can utilize casein or gelatin as a substrate. 
 
Serum concentrations of Mmp-9 with gelatinolytic activity were identified by electrophoresis 
in 7.5% SDS-polyacrylamide gels containing 0.1% gelatine as protease substrate. 22.5 µl of 
1:10 diluted serum samples were added to the non-reducing sample buffer and loaded on 
sodium dodecyl sulfate (SDS)-polyacrylamide gel. 0.5 ng of recombinant mouse Mmp-9 
(AnaSpec) was used as control. Electrophoresis was performed at 20 mA for 0.5 h and then 
at 30 mA for 1 h at 4°C. Gels were rinsed twice with 2.5% Triton X-100 to remove SDS and 
renature the Mmps. After a brief wash, gels were incubated overnight in reaction buffer (50 
mM TRIS-HCL, 5 nM CaCl2, 0.1% TRITON X-100, pH 7.8) at 37°C with gentle agitation. The 
gels were stained with Coomassie Blue (Invitrogen) and Mmp-9 activity was detected as 
transparent bands on blue background where the protease has digested the substrate (Lantz 
and Ciborowski 1994). 
2.6.2 Matrigel invasion assay 
Matrigel is the trade name for a protein mixture that is extracted from the Engelbreth-Holm-
Swarm (EHS) mouse sarcoma, a tumor rich in extracellular matrix proteins. During invasion 
experiments the Matrigel matrix serves as a reconstituted basement membrane in vitro, 
blocking non-invasive cells from migrating through the membrane. In contrast, invasive cells 
(malignant and non-malignant) secrete proteases (like metalloproteinases) that enzymatically 
degrade the Matrigel matrix and enable invasion through the membrane pores (Hughes, 
Postovit et al. 2010). 
 
Invasion assays were performed with BMD macrophages in 24-well chambers with inserts (8 
µm pores) coated with matrigel (BD BioCoat Matrigel Invasion Chamber, Catalog number 
354480). 5 x 105 cells were added to the upper chamber and allowed to attach for 3 h. 
Unattached cells were removed by washing twice with warm PBS. 1 ml DMEM with 10 µl 
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Mcp-1 (10 ng/ml, R&D Systems) as chemoattractant was added into the lower chamber. 
DMEM (500 µl) with 5 µl plasminogen (10 µg/ml, Sigma Aldrich) was added into the upper 
chamber. The plates were incubated for 24 h (37°C, 5% CO2). After incubation non-invading 
cells were removed from the upper surface of the membrane with PBS and gentle scrubbing 
with a sterile cotton bud. Cells on the lower surface of the membrane were fixed with 4% 
formaldehyde for 10 min at RT. Inserts were washed with running tap water for 10 min and 
stained with Hematoxylin (Sigma Aldrich). After another water rinse the membrane of the 
inserts was cut out and mounted on glass slides with glycerol gelatine. Cells were counted in 
4 visual fields in 3 representative membranes per genotype, respectively (objective lens, 
20x). 
 
The same experiment was performed with macrophages harvested from peritoneal cavity 
after the induction of a sterile peritonitis with 3% Brewer thioglycollate medium 3 days prior to 
harvesting. 
2.7 Statistical analysis 
All data are given as mean ± standard deviation unless otherwise indicated. Normality of 
distribution was assessed using the Kolmogorov–Smirnov test implemented in PRISM 
statistical software (GraphPad). Comparison of multiple groups was done using ANOVA, and 
Tukey was performed as post-test. Comparison of two groups of normally distributed 
samples was done using the t-test. 
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3 Results 
3.1 Influence of Nfkb2 deficiency on atherosclerotic lesion development 
3.1.1 Tissue specific Nfkb2 expression analyses 
To investigate the gene expression pattern of the Nfkb2 gene, we performed tissue specific 
Nfkb2 expression analysis in 8 weeks old Nfkb2+/+ mice on the Ldlr-/- background (Figure 12). 
 
 
Figure 12. Expression of Nfkb2 in organs from Nfkb2
+/+
Ldlr
-/-
 mice. Experiments were run in 
quadruplicates. Values are given as mean + SEM (n = 6). 
 
Corresponding to the important role of Nf-kb2 in secondary lymphoid organ development, 
highest expression of Nfkb2 could be observed in spleen and thymus. However, there was 
also ample expression in other tissues, namely heart and aorta, indicating the presence of 
Nf-kb2 in the vasculature (Figure 12). 
 
Different segments of the vascular system display diverging susceptibility to atherosclerotic 
lesion development. We defined segments of the vasculature, namely the aortic root, the 
brachiocephalic artery, the aortic arch, and the thoracic aorta (Figure 13 A) and determined 
Nfkb2 transcription with quantitative RT-PCR. Segments were obtained by microdissection 
from 8-week-old Nfkb2+/+Ldlr-/- mice that had not yet exhibited any atherosclerotic lesion 
development. 
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Expression analysis revealed that Nfkb2 expression was highest at the brachiocepahilc 
artery where oscillatory shear stress patterns occur (Figure 13 B). 
 
 
Figure 13. Nfkb2 mRNA expression in defined vascular segments. (A) Defined segments of the 
vascular bed with different susceptibility to atherosclerotic lesion development (brachiocephalic artery 
(BCA), aortic root (AR), aortic arch (AA), thoracic aorta (TA)). (B) Nfkb2 expression is determined as 
copies per µg RNA in defined vascular segments of Nfkb2
+/+
Ldlr
-/-
 mice (8 weeks of age; n = 6). 
Experiments were run in quadruplicates. Values are given as mean + SEM. *** (P < 0.001);** (P < 
0.01). 
 
3.1.2 Identification of Nf-kb2 in atherosclerotic lesions 
To investigate if Nf-kb2 is present in atherosclerotic lesions, we performed immuno-
histochemistry using an Nf-kb2-specific antibody in frozen sections of the BCA of female 
Nfkb2+/+Apoe-/- mice. Figure 14 shows a representative slide of Nf-kb2 staining with Nf-kb2 
positive cells stained in brown. Nf-kb2 was detected in the adventitia, the vessel wall, and the 
actual plaque (Figure 14), suggesting that it might play a role in atherogenesis. 
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Figure 14. Nf-kb2 protein localization in atherosclerotic lesions. BCA cryosections of female  
Apoe
-/-
 mice (20 weeks of age) were stained with p100/p52 specific antibody (dilution 1:100) and 
counterstained with hematoxylin. Nf-kb2 positive cells are stained in brown. 
 
3.1.3 Generation of Nfkb2-/- knockout mice 
For atherosclerotic experiments, Nfkb2-/- mice were bred on the Apoe- and Ldlr-deficient 
background as pure C57BL/6 mice do not spontaneously develop atherosclerotic lesions. 
Both, knockout of the Apoe and the Ldlr gene, represent atherosclerotic mouse models with 
different mechanisms of increased atherosclerosis-susceptibility, respectively. Mice lacking 
Apoe have plasma cholesterol levels that are 4 to 5 times higher than normal and develop 
atherosclerotic lesions spontaneously, even when fed a normal chow diet, which is low in fat 
and cholesterol (Nakashima, Plump et al. 1994; Reddick, Zhang et al. 1994). Mice lacking 
the Ldlr have less overt disease, with a modest 2 times normal plasma cholesterol level 
when maintained on a normal chow diet, and they develop atherosclerosis only slowly 
(Merat, Fruebis et al. 2000). However, in response to a high-fat, high-cholesterol diet, Ldlr-
deficient mice exhibit massive elevations in plasma cholesterol and rapidly develop 
atherosclerotic lesions throughout the aorta (Ishibashi, Goldstein et al. 1994). 
 
Homozygous Nfkb2 knockout animals were obtained from heterozygous parents with the 
expected Mendelian frequency. At 4 weeks of age mice were weaned on standard chow for 
p100/p52
200µm
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expression analyses. For atherosclerotic experiments mice were weaned on a low fat 
semisynthetic diet containing 0.02% cholesterol which has previously been shown to 
promote hypercholesterolemia and atherosclerosis while avoiding obesity with its attendant 
metabolic complications (Teupser, Persky et al. 2003). Neither heterozygous nor 
homozygous Nfkb2-deficient mice exhibited any gross abnormalities and proved healthy and 
fertile when maintained under specific pathogen free conditions. 
3.1.4 Characterization of the Nfkb2-/- phenotype 
Mice were sacrificed at 20 weeks of age by a standardized protocol. Plasma parameters 
were analysed in an automated analyser (Modular PPE, Roche) and lipoproteins were 
isolated by sequential ultracentrifugation. Total body weight and biochemical characteristics 
of female and male Nfkb2+/+, Nfkb2+/-, and Nfkb2-/- mice on the Apoe- and Ldlr-deficient 
background are indicated in Table 11 and Table 12, respectively. 
 
Table 11. Total body weight and biochemical characteristics of female and male Nfkb2
+/+
/ 
Nfkb2
+/- 
/ Nfkb2
-/-
 mice on the Apoe
-/-
 background. 
Female Apoe
-/-
 
  Nfkb2
+/+ 
Nfkb2
+/- 
Nfkb2
-/-
  
 Unit Mean SD Mean SD Mean SD P-Value 
Mice (n)  20 20 20  
Body weight g 21.27 1.67 21.87 1.43 21.51 1.51 0.494 
Chol mmol/l 10.38 1.38 11.39 3.27 11.44 3.79 0.516 
Tg mmol/l 0.98 0.49 1.38 0.91 1.28 0.67 0.207 
Vldl-c (ultracentr.) mmol/l 3.92 1.26 4.76 2.32 5.10 2.39 0.242 
Ldl-c (ultracentr.) mmol/l 5.88 0.96 6.07 1.28 5.71 1.60 0.749 
Hdl-c (ultracentr.) mmol/l 0.59 0.14 0.57 0.17 0.63 0.18 0.610 
Alat µkat/l 0.43 0.16 0.49 0.17 0.74 0.39 0.001 
Asat µkat/l 2.02 0.97 2.45 1.41 3.14 2.45 0.139 
Che µkat/l 126.04 8.96 126.06 11.65 125.50 13.18 0.985 
Gldh µkat/l 0.22 0.12 0.26 0.11 0.35 0.19 0.020 
Protein g/l 47.58 3.20 47.85 3.33 45.98 4.53 0.249 
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Male Apoe
-/-
 
  Nfkb2
+/+ 
Nfkb2
+/- 
Nfkb2
-/-
  
 Unit Mean SD Mean SD Mean SD P-Value 
Mice (n)  20 20 20  
Body weight g 29.67 2.87 30.12 4.37 26.88 3.27 0.023 
Chol mmol/l 14.50 4.14 14.25 3.18 15.48 3.64 0.617 
Tg mmol/l 1.65 1.04 1.65 0.78 2.06 1.19 0.427 
Vldl-c (ultracentr.) mmol/l 5.95 2.80 5.78 1.78 6.86 2.36 0.401 
Ldl-c (ultracentr.) mmol/l 7.76 1.63 7.73 1.92 7.93 1.72 0.940 
Hdl-c (ultracentr.) mmol/l 0.79 0.17 0.74 0.28 0.69 0.18 0.393 
Alat µkat/l 0.62 0.31 0.89 0.66 0.77 0.27 0.198 
Asat µkat/l 1.50 0.78 2.48 2.23 2.26 1.45 0.158 
Che µkat/l 81.28 10.32 87.69 11.67 86.30 14.97 0.268 
Gldh µkat/l 0.33 0.19 0.46 0.26 0.55 0.28 0.032 
Protein g/l 45.87 2.33 46.94 3.96 46.40 3.49 0.627 
Parameters are given in standard international units. All data are given as mean ± standard deviation. 
Cholesterol concentrations of lipoprotein subfractions are framed. Chol: Cholesterol, Tg: Triglycerides, 
Vldl-c: Very low densitiy lipoprotein- cholesterol, Ldl-c: Low density lipoprotein- cholesterol, Hdl-c: High 
density lipoprotein-cholesterol, Alat: Alanine transaminase, Asat: Aspartate transaminase, Che: 
Cholinesterase, Gldh: Glutamate dehydrogenase. 
 
Table 12. Total body weight and biochemical characteristics of female and male Nfkb2
+/+
/  
Nfkb2
-/-
 mice on the Ldlr
-/-
 background. 
Female Ldlr
-/-
 
  Nfkb2
+/+ 
Nfkb2
-/-  
 Unit Mean SD Mean SD P-Value 
Mice (n)  16 14  
Body weight g 20.71 1.20 19.48 1.70 0.028 
Chol mmol/l 9.88 3.33 9.38 1.63 0.624 
Tg mmol/l 1.52 0.59 0.87 0.35 0.001 
Vldl-c (ultracentr.) mmol/l 2.13 1.08 0.95 0.45 0.001 
Ldl-c (ultracentr.) mmol/l 7.10 1.34 6.92 1.38 0.734 
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Hdl-c (ultracentr.) mmol/l 1.31 0.22 1.50 0.24 0.034 
Alat µkat/l 0.52 0.12 0.48 0.17 0.528 
Asat µkat/l 1.46 0.54 1.52 0.50 0.754 
Che µkat/l 102.11 12.91 105.71 15.62 0.502 
Gldh µkat/l 0.14 0.04 0.15 0.07 0.827 
Protein g/l 43.81 2.26 40.63 3.40 0.006 
Male Ldlr 
-/-
 
  Nfkb2
+/+ 
Nfkb2
-/-  
 Unit Mean SD Mean SD P-Value 
Mice (n)  14 17  
Body weight g 28.15 2.05 24.39 0.94 <0.001 
Chol mmol/l 9.37 1.95 10.02 1.87 0.352 
Tg mmol/l 1.37 0.57 1.34 0.50 0.880 
Vldl-c (ultracentr.) mmol/l 1.08 0.65 1.09 0.76 0.972 
Ldl-c (ultracentr.) mmol/l 6.26 1.38 7.11 1.21 0.077 
Hdl-c (ultracentr.) mmol/l 2.03 0.21 1.82 0.22 0.010 
Alat µkat/l 0.46 0.17 0.54 0.14 0.177 
Asat µkat/l 1.21 0.41 1.21 0.51 0.985 
Che µkat/l 80.23 8.55 64.87 7.88 <0.001 
Gldh µkat/l 0.12 0.06 0.11 0.03 0.390 
Protein g/l 46.49 3.25 41.41 4.69 0.002 
Parameters are given in standard international units. All data are given as mean ± standard deviation. 
Cholesterol concentrations of lipoprotein subfractions are framed. Chol: Cholesterol, Tg: Triglycerides, 
Vldl-c: Very low densitiy lipoprotein- cholesterol, Ldl-c: Low density lipoprotein- cholesterol, Hdl-c: High 
density lipoprotein-cholesterol, Alat: Alanine transaminase, Asat: Aspartate transaminase, Che: 
Cholinesterase, Gldh: Glutamate dehydrogenase. 
 
On the Apoe-deficient background plasma parameters did not substantially differ between 
Nfkb2-/- mice and Nfkb2+/+ controls. Liver enzymes were slightly elevated in female (Alat, 
Gldh) and male (Gldh) double knockout mice. Cholesterol fractions of lipoproteins that had 
been isolated by ultracentrifugation, displayed no differences for both sexes (Table 11).  
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On the Ldlr-deficient background male Nfkb2-/- mice had markedly lower levels of 
cholinesterase and total plasma protein levels, indicating reduced protein synthesis in the 
livers of these mice. In regard to the protein level we found the same effect in female Nfkb2-/-
Ldlr-/- mice. Importantly, female Nfkb2-/-Ldlr-/- mice had significantly reduced Tg- and Vldl-c-, 
and elevated Hdl-c- levels. Both, Tg and Vldl have been shown to have atherosclerosis 
promoting abilities, while Hdl is regarded as athero-protective. Total amounts of cholesterol 
and Ldl-cholsterol did not significantly differ in female and male Nfkb2+/+Ldlr-/- and Nfkb2-/-
Ldlr-/- mice (Table 12). 
 
On the Ldlr-deficient background female and male Nfkb2-/- mice were significantly smaller 
than wildtype controls (Table 12) (Figure 15). On the Apoe-deficient background this effect of 
the Nfkb2 knockout was only observed in male animals whereas female Nfkb2-/-Apoe-/- mice 
displayed no significant weight differences (Table 11) (Figure 15). 
 
 
Figure 15. Total body weight of Apoe
-/-
 (A+B) and Ldlr
-/-
 (C+D) mice. Animal numbers are given in 
the columns. Values are given as mean + SEM. *** (P < 0.001); *(P < 0.05). 
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3.1.5 Quantification of atherosclerotic lesions in Nfkb2-/- mice 
To investigate the role of Nf-kb2 in atherogenesis we performed quantification of 
atherosclerotic lesions at Oil Red O-stained sections of the aortic root and the 
brachiocephalic artery of Nfkb2-/- mice and wildtype controls on the Apoe- and Ldlr-deficient 
background at 20 weeks of age. 
 
In general, Nfkb2-deficiency was associated with increased atherosclerosis susceptibility on 
the Apoe-/- and Ldlr-/- background. On the Apoe-/- background, lesion development was 
significantly elevated in Nfkb2-/- mice at the aortic root (1.3-fold in females, 1.5-fold in males) 
as well as at the BCA (2-fold in females and males). Consistent with previous studies of our 
group, Ldlr-/- mice developed significantly smaller atherosclerotic lesions than Apoe-/- mice, 
however, we observed a trend toward increased plaque size in Nfkb2-/-Ldlr-/- mice which 
reached the level of statistical significance in male BCAs (2.6-fold) (Figure 16). 
 
 
Figure 16. Atherosclerotic lesion development in Nfkb2
-/-
 mice. Lesion areas (µm
2
) were 
investigated at the aortic root (AR) and the brachiocephalic artery (BCA) on the Apoe- (A+B) and Ldlr- 
(C+D) deficient background. Animal numbers are given in the columns. Values are given as mean + 
SEM. ** (P < 0.01); *(P < 0.05). 
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In summary, we found that Nf-kb2 is present in the vasculature and atherosclerotic lesions 
and has a protective effect on atherosclerotic lesion development. This effect was 
independent of total amount of plasma cholesterol and particularly Ldl-cholesterol which did 
not differ between Nfkb2-/- mice and wildtype controls. The pro-atherogenetic effect of the 
Nfkb2 knockout was most obvious at the brachiocephalic artery consistent with elevated 
Nfkb2 expression in this segment of the vascular bed. 
3.2 Identification of Nf-kb2 specific target genes in BMDM and organs 
In the pathogenesis of atherosclerotic lesion development macrophage-driven immune 
mechanism play an important role. The Nf-kb transcription factor family represents a central 
signaling component in the inflammatory response of macrophages (Hansson and 
Hermansson 2011) (Figure 2). To date, no study has investigated the influence of the Nfkb2 
knockout on macrophage gene expression. All “Nf-kb2 specific target genes” which have 
been identified so far are organic chemokines, critical for spleen organogenesis and 
maintenance of tissue-microarchitecture (Bonizzi, Bebien et al. 2004). In most cells, 
however, Nf-kb2 (p100/p52) is mostly present as cytoplasmatic p100 which was shown to act 
as inhibitor of classical Nf-kb1 activation (Basak, Kim et al. 2007). Thus, it is likely to assume 
that many genes are indirectly regulated by the alternative Nf-kb2 pathway. 
3.2.1 Whole genome analysis in Nfkb2-/- BMDM 
To identify p100/p52 specific target genes that might have influenced enhanced 
atherosclerotic lesion development in Nfkb2-/- mice, we performed whole genome expression 
analysis in bone marrow-derived macrophages from Nfkb2-/- mice and wildtype controls. 
Microarray experiments were performed on the Ldlr- (chip 1) and Apoe- (chip 2) deficient 
background.  
 
Statistical analysis of expression data in Apoe-/- BMDM revealed 3119 differentially 
expressed genes (P-value < 0.01). Table 13 shows the most differentially expressed genes 
sorted by fold change (FC) (Ratio: knockout to wildtype, Cut-off: FC > 3; < 0.35). 
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Table 13. Illumina Ref-8 whole genome analysis in BMDM of Nfkb2
+/+
 and Nfkb2
-/-
 mice on the 
Apoe
-/-
 background. 
Apoe
-/-
 Symbol FC Nfkb2
+/+
 Nfkb2
-/-
 Description 
U
p
-r
e
g
u
la
te
d
 i
n
 N
fk
b
2
-/
-  
B
M
D
M
 
Il4i1 10.51 32 340 Interleukin 4 induced protein 1 
Gpr120 9.72 14 137 G protein-coupled receptor 120 
Serinc2 7.71 22 171 Serine incorporator 2 
Myo1b 6.67 16 107 Myosin 1b 
Lat 5.86 20 117 Linker for activation of T cells 
Ctsk 5.76 484 2790 Cathepsin K 
Pde4dip 4.77 148 708 Phosphodiesterase 4D interacting protein 
Mefv 4.76 136 648 Mediterranean fever gene 
Vldlr 4.70 31 145 Very low density lipoprotein receptor 
Gpc1 4.62 400 1850 Glypican 1 
Mmp9 4.12 27 110 Matrixmetalloproteinase 9 
Cxcl10 3.98 283 1125 Chemokine ligand 10 
H2-M2 3.87 267 1034 Histocompatibility 2. M region locus 2 
Vegfc 3.69 863 3183 Vascular endothelial growth factor C 
Slc7a11 3.40 37 127 Solute carrier family 7 member 11 
Tnc 3.34 30 101 Tenascin C 
Gpr68 3.31 89 294 G protein-coupled receptor 68 
Prkcdbp 3.20 40 129 Protein kinase C delta binding protein 
Tm7sf4 3.10 170 526 Transmembrane 7 superfamily member 4 
Apoe
-/-
 Symbol FC Nfkb2
+/+
 Nfkb2
-/-
 Description 
D
o
w
n
-r
e
g
u
la
te
d
 
in
 N
fk
b
2
-/
-  
B
M
D
M
 
Slc40a1 0.22 2002 444 Solute carrier family 40  
Gpr84 0.31 752 231 G protein-coupled receptor 84 
Nfkb2 0.32 309 100 Nuclear factor kappa B 2 
Sort1 0.34 1535 523 Sortilin 1 
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Statistical analysis of expression data in Ldlr-/- BMDM revealed 1128 differentially expressed 
genes (P-value < 0.01). Table 14 shows the most differentially expressed genes sorted by 
fold change (FC) (Ratio: knockout to wildtype, Cut-off: FC > 3; < 0.35). 
 
Table 14. Illumina Ref-8 whole genome analysis in BMDM of Nfkb2
+/+
 and Nfkb2
-/-
 mice on the 
Ldlr
-/-
 background. 
Ldlr
-/-
 Symbol FC Nfkb2
+/+
 Nfkb2
-/-
 Description 
U
p
-r
e
g
u
la
te
d
 i
n
 N
fk
b
2
-/
-  
B
M
D
M
 Mmp9 15.64 107 1680 Matrixmetalloproteinase 9 
Il4i1 6.78 127 858 Interleukin 4 induced protein 1 
Cyp1b1 4.02 109 439 Cytochrome P450 subfamily 1 polypeptide 1 
Hvcn1 3.87 618 2444 Hydrogen voltage-gated channel 1  
Mefv 3.72 162 601 Mediterranean fever gene 
Asb2 3.59 66 238 Ankyrin repeat and SOCS box-containing 2 
Ctsk 3.24 2830 9174 Cathepsin K 
Il1rn 3.09 596 1841 Interleukin 1 receptor antagonist  
Ldlr
-/-
 Symbol FC Nfkb2
+/+
 Nfkb2
-/-
 Description 
D
o
w
n
-r
e
g
u
la
te
d
 i
n
 N
fk
b
2
-/
-  
B
M
D
M
 
Arl3 0.24 609 143 ADP-ribosylation factor-like 3 
Eef1a2 0.26 1388 348 Eukaryotic translation elong. factor 1 alpha 2 
Igf1 0.27 1779 489 Insulin-like growth factor 1 
Gpr84 0.29 1728 506 G protein-coupled receptor 84 
Fpr-rs2 0.32 762 242 Formyl peptide receptor 2 
Sort1 0.32 1054 339 Sortilin 1 
Htr2b 0.33 385 127 5-hydroxytryptamine (serotonin) receptor 2B  
Ccl4 0.33 3983 1320 Chemokine (C-C motif) ligand 4  
 
In summary, we identified more than 1000 Nf-kb2 specific target genes in BMD 
macrophages. A large part of differentially expressed genes were significantly up-regulated 
in Nfkb2-/- mice. Differentially expressed genes were confirmed on both (Apoe-/- and Ldlr-/-) 
backgrounds (Table 13 and Table 14). Analysis of the fold change ratio of differentially 
regulated genes revealed significant correlation on both backgrounds (P < 0.0001, r = 0.642; 
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Figure 17). Highest differences could be found for matrix metalloproteinase 9 (Mmp9) (FC: 
15.64; Ldlr-/-) and interleukin 4 induced protein 1 (Il4i1) (FC: 10.51; Apoe-/-) (Figure 17). 
 
 
Figure 17. Fold change ratio (K0/Wt) of chip 1 (Ldlr
-/-
) and chip 2 (Apoe
-/-
). Fold change ratio in 
gene expression of Nfkb2
-/-
 mice and Nfkb2
+/+
 mice on the Ldlr
-/-
 background (Chip 1) was correlated 
with the fold change ratio in gene expression of Nfkb2
-/-
 mice and Nfkb2
+/+
 mice on the Apoe
-/-
 
background (Chip 2). Spearman r = 0.642, P < 0.0001. 
 
Mmp-9 (also named Gelatinase B) belongs to a family of endopeptidases capable of cleaving 
components of the extracellular matrix, which have been shown to affect atherosclerotic 
lesion formation in mice and humans. Il4i1, a leukocyte L-amino acid oxidase with lysosomal 
localization, is induced as early response gene from Il-4, a key regulator of the immune 
response. 
3.2.2 Differential regulation of Nf-kb2 target genes in BMDM and organs 
Overexpression of Mmp9 and Il4i1 in Nfkb2-/- BMDM could be confirmed by quantitative RT-
PCR. Macrophages were further stimulated with LIGHT, a ligand for lymphotoxin beta 
receptor, and LPS. Activation of the Ltr leads to p100 processing and thereby liberation of 
active p52 dimers (Dejardin, Droin et al. 2002), whereas stimulation with LPS activates the 
classical Nf-kb1 pathway by toll-like receptor signaling (Figure 4). 
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On the Apoe-/- background, Mmp9 was up-regulated 25-fold, while on the Ldlr-/- background 
we found a more than 100-fold overexpression of Mmp9 in Nfkb2-/- macrophages compared 
to wildtype controls. As expected stimulation with LIGHT did not affect Mmp9 expression in 
Nfkb2+/+, Nfkb2+/- or Nfkb2-/- mice. Interestingly, however, stimulation with LPS was not able 
to enhance Mmp9 expression either (Figure 18). 
 
 
Figure 18. Mmp9 mRNA expression in Nfkb2
-/-
Apoe
-/-
 and Nfkb2
-/-
Ldlr
-/-
 BMDM. Macrophages 
were stimulated with LIGHT (100ng/ml), LPS (1µg/ml) or Medium control for 8h and total mRNA 
expression was quantified with RT-PCR. Ba was used as housekeeping gene. Experiments were run 
in quadruplicates. Sample numbers are given in the columns. Values are given as mean + SEM. *** (P 
< 0.001); ** (P < 0.01). 
 
These findings indicate that the alternative Nf-kb2 pathway has important regulatory 
functions for constitutive Mmp9 expression in murine macrophages. 
 
The same effect was found for Il4i1 which was up-regulated 8-fold on the Apoe-/- and 40-fold 
on the Ldlr-/- background. In contrast to Mmp9, overexpression of Il4i1 could be enhanced by 
stimulation with LPS (Figure 19). 
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Figure 19. Il4i1 mRNA expression in Nfkb2
-/-
Apoe
-/-
 and Nfkb2
-/-
Ldlr
-/-
 BMDM. Macrophages were 
stimulated with LIGHT (100ng/ml), LPS (1µg/ml) or Medium control for 8h and total mRNA expression 
was quantified with RT-PCR. Ba was used as housekeeping gene. Experiments were run in 
quadruplicates. Sample numbers are given in the columns. Values are given as mean + SEM. *** (P < 
0.001); ** (P < 0.01); *(P < 0.05). 
 
 
Figure 20. Mmp9 mRNA expression in Nfkb2
-/-
Apoe
-/-
 (A+B) and Nfkb2
-/-
Ldlr
-/-
 (C+D) 
parenchymatous organs. Total mRNA expression in liver and spleen was quantified with RT-PCR. 
Ba was used as housekeeping gene. Experiments were run in quadruplicates. Sample numbers are 
given in the columns. Values are given as mean + SEM. *** (P < 0.001); ** (P < 0.01); *(P < 0.05). 
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Further expression analyses revealed that overexpression of Mmp9 in Nfkb2-/- mice could 
also be observed in parenchymatous organs like spleen and liver (Figure 20), whereas Il4i1 
showed contrary results. In fact, Il4i1 expression was significantly reduced in spleens of 
Nfkb2-/- mice, indicating diverging regulatory mechanisms for this protein in different cell 
types (Figure 21). 
 
 
Figure 21. Il4i1 mRNA expression in Nfkb2
-/-
Apoe
-/-
 (A+B) and Nfkb2
-/-
Ldlr
-/-
 (C+D) 
parenchymatous organs. Total mRNA expression was quantified with RT-PCR. Ba was used as 
housekeeping gene. Experiments were run in quadruplicates. Sample numbers are given in the 
columns. Values are given as mean + SEM. *** (P < 0.001); ** (P < 0.01); *(P < 0.05). 
 
In summary, we found that the knockout of the Nf-kb2 protein led to highly significant 
induction of Mmp9 and Il4i1 transcription in murine BMD macrophages. Overexpression of 
Mmp9 could not be further augmented by stimulation with LPS, implying important regulatory 
functions for the alternative Nf-kb2 pathway in constitutive Mmp9 expression. 
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3.3 Functional analyses of Nfkb2-/- macrophage properties in vitro 
To confirm the biological significance of this finding, we performed functional analyses which 
addressed Mmp-9 activity and Nfkb2-/- macrophage properties in vitro. 
3.3.1 Mmp-9 activity in serum of Nfkb2-/- mice 
To verify differential Mmp9 expression on the protein level, we performed serum gelatin 
zymography. Serum was obtained from Nfkb2-/- and Nfkb2+/+ mice and assayed for 
gelantinolytic activity. A single band of ~92kDa corresponded to Mmp-9 on the zymogram. 
Mmp-9 activity was detected as transparent bands on a blue background (Figure 22).  
 
 
Figure 22. SDS Page zymography in serum of Nfkb2
+/+
 and Nfkb2
-/- 
mice. Serum concentrations of 
Mmp-9 with gelatinolytic activity were identified by electrophoresis in 7.5% SDS-polyacrylamide gels 
containing 0.1% gelatine as protease substrate. Gels were stained with Coomassie
TM 
Blue and Mmp-9 
activitiy was detected as transparent bands on blue background. Recombinant mouse Mmp-9 (0.5 ng) 
was used as control (ctr).  
 
In accordance with our finding of increased Mmp9 expression in macrophages of Nfkb2-/- 
mice, digestion of Gelatin was much higher in the serum of Nfkb2-/- mice, indicating 
increased Mmp-9 activity. 
3.3.2 Nf-kb2 macrophage invasion in vitro 
Enhanced Mmp-9 enzymatic activity of Nfkb2-/- macrophages was further confirmed by 
Matrigel invasion experiments. Matrigel thereby served as a reconstituted basement 
membrane in vitro which can only be penetrated by secretion of proteases like 
Nfkb2+/+        Nfkb2-/- Ctr
Mmp9 ~ 92kDa
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metalloproteinases that enzymatically degrade the Matrigel matrix. Macrophages of Nfkb2+/+ 
and Nfkb2-/- mice were further stimulated with Plasminogen which has been shown to 
activate Mmp-9 and thereby enforcing macrophage migration activity (Gong, Hart et al. 
2008). Monocyte chemoattractant protein-1 was used as chemoattractant. 
 
In separate experiments we found that invasion of Nfkb2-/- macrophages was significantly 
increased compared to wildtype controls (Figure 23). 
 
 
Figure 23. Plasminogen-induced Nfkb2
-/-
 macrophage migration across ECM in vitro. (A) 
Invasion assays were performed with BMD macrophages in 24-well chambers with inserts (8 µm 
pores) coated with matrigel. Mcp-1 (10 ng/ml) was used as chemoattractant. (B) Cells were counted in 
4 visual fields in 2 representative membranes per genotype, respectively. 
 
These data demonstrate that upregulation of Mmp9 in Nfkb2-/- macrophages plays an 
essential role in Plasminogen-induced macrophage migration across ECM in vitro. 
Overexpression of Mmp9 in Nfkb2-/- mice is thus likely to have contributed to increased 
inflammatory cell migration in the atheroma and thereby atherosclerotic lesion development. 
3.4 Immunohistological characterization of plaque composition (plaque 
phenotyping) 
To confirm this hypothesis, we performed immunohistochemistry and a modified Stary 
classification of atherosclerotic plaques in the brachiocephalic arteries of female 
Nfkb2+/+Apoe-/- and Nfkb2-/-Apoe-/- mice. 
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The analysis revealed that Nfkb2-/- mice suffered from major lesions which were highly 
positive for Cd68 macrophages, smooth muscle cells and Mmp-9, indicating an inflammatory 
plaque phenotype (Figure 24). 
 
 
Figure 24. Plaque phenotyping in Nfkb2
+/+
 and Nfkb2
-/-
 mice. Immunohistochemistry in frozen 
sections of the BCA of female Nfkb2
+/+
Apoe
-/- 
and Nfkb2
-/-
Apoe
-/-
 mice (20 weeks of age). Staining was 
performed with antibodies against macrophages (Cd68), smooth muscle cells (Sma), and Mmp-9. 
Counterstaining was performed with hematoxylin. 
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Staining patterns of Mmp-9 mirrored those of Cd68, suggesting enhanced Mmp-9 production 
by resident macrophages. In contrast to Nfkb2-/- mice, wildtype plaques exhibited only 
moderate Mmp-9 staining. 
 
Lesion composition was tested by Oil Red O staining for lipids. As shown in Figure 25, 
female Nfkb2-/-Apoe-/- mice had significantly larger numbers of advanced lesions (stage 2 and 
3) with complex fibro-proliferative plaques and sometimes necrotic cores. Nfkb2+/+Apoe-/- 
mice primarily displayed early lesion consisting predominantly of foam cells (stage 0 and 1). 
The extent of arterial wall inflammation was estimated by the degree of degradation of 
collagen and elastic fibres and classified into none, moderate, and severe wall inflammation. 
We found that Nfkb2-/- mice had a markedly higher percentage of severe wall inflammation 
than Nfkb2 wildtype controls (Figure 25). 
 
 
Figure 25. Classification of atherosclerotic lesion composition in the BCAs of female Nfkb2
+/+ 
Apoe
-/-
, Nfkb2
+/-
Apoe
-/-
, and Nfkb2
-/-
Apoe
-/-
 mice. Modified Stary classicication (A+B) and arterial 
wall inflammation (C+D) at Oil Red O stained cryosection of the BCA (n = 20 (Nfkb2
+/+
Apoe
-/-
), 17 
(Nfkb2
+/-
Apoe
-/-
), 19 (Nfkb2
-/-
Apoe
-/-
), corresponding to Figure 16B). Values are given in percent. 
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In summary, these data indicate that overexpression of Mmp9 in Nfkb2-/- mice resulted in an 
inflammatory plaque phenotype with advanced, macrophage-rich lesions. 
3.4.1 Detection of Il4i1 in atherosclerotic lesions 
In previous experiments we showed that expression of Il4i1 was highly increased in Nfkb2-/- 
macrophages. According to the literature, Il4i1 is primarily expressed in immune tissues, with 
highest levels in spleen and thymus, followed by placenta and lung. To our knowledge no 
study has yet addressed the question of whether Il4i1 might have an impact on 
atherogenesis. We therefore performed Immunohistochemstry with an Il4i1 specific antibody 
to find out if Il4i1 is present in atherosclerotic lesions. 
 
Immunohistochemical analysis revealed that Il4i1 can be readily observed in atherosclerotic 
lesions, especially in plaque-associated adventitia (Figure 26). 
 
 
Figure 26. Detection of Il4i1 in atherosclerotic lesions. Immunohistochemistry in frozen sections of 
the BCA of female Nfkb2
+/+
Apoe
-/- 
and Nfkb2
-/-
Apoe
-/-
 mice (20 weeks of age). Staining was performed 
with Il4i1 specific antibody, and counterstaining was performed with hematoxylin. Il4i1 positive cells 
are given as brown dots. 
 
This finding provides evidence that increased Il4i1 expression might also have contributed to 
enhanced atherosclerotic lesion development in Nfkb2-/- mice. 
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3.5 Molecular mechanisms of Nfkb2 deficiency 
Expression analyses in BMDM of Nfkb2-/- mice and wildtype controls revealed that many 
genes are strongly induced in Nfkb2-/- mice, especially Mmp9 and Il4i1. We hypothesized that 
induction of target genes in these mice was caused by the lack of the inhibitory precursor 
protein p100. Recent studies have provided evidence that p100 has important regulatory 
functions within the Nf-kb signaling system, and can inhibit activation of Nf-kb-complexes by 
multiple cross regulatory mechanisms (Solan, Miyoshi et al. 2002; Basak, Kim et al. 2007). 
 
To confirm this hypothesis we repeated verification of target genes in p100 knockout mice. 
P100-/- mice are generated by the targeted disruption of the COOH-terminal ankyrin repeats 
of Nf-kb2. Thus, they are suffering from a lack of p100 but still contain a functional p52 
protein. These mice display marked gastric- and lymphoid hyperplasia and early postnatal 
lethality (Ishikawa, Carrasco et al. 1997). P100-/- mice were obtained from Prof. Falk Weih 
(FLI, Jena) and BMD macrophages were used for expression analyses. 
We found, that Mmp9 and Il4i1 were highly significantly up-regulated in p100-/- mice 
compared to wildtype controls. Mmp9 was up-regulated by approximately 70-fold and Il4i1 
was up-regulated by approximately 50-fold (Figure 27). Comparable to our findings in Nfkb2-/- 
mice, stimulation of macrophages with LPS did not affect Mmp9 transcription, whereas Il4i1 
expression was significantly induced (Figure 27). 
 
 
Figure 27. Expression of Mmp9 and Il4i1 mRNA in p100 BMDM. (A) Expression of Mmp9 in p100 
macrophages. (B) Expression of Il4i1 in p100
 
macrophages. Macrophages were stimulated with 
LIGHT (100ng/ml), LPS (1µg/ml), or Medium control for 8h and total mRNA expression was quantified 
with RT-PCR. Ba was used as housekeeping gene. Experiments were run in quadruplicates. Sample 
numbers are given in the columns. Values are given as mean + SEM. *** (P < 0.001); *(P < 0.05). 
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These findings demonstrate that that the lack of the inhibitory precursor p100 is most likely to 
account for increased Mmp9 and Il4i1 expression in Nfkb2-/- mice.  
 
As mentioned above p100 can inhibit the nuclear translocation of Nf-kb dimers. This Ikb-like 
function of p100 has been shown for Rela and Relb containing complexes (Solan, Miyoshi et 
al. 2002; Basak, Kim et al. 2007). Especially Basak and Hoffmann established p100 as 
important regulator of classical Nf-kb1 signaling (Basak, Kim et al. 2007; Basak and 
Hoffmann 2008). As Mmp9 has been identified as Nf-kb1 (p105/p50) target gene in various 
studies (Bond, Fabunmi et al. 1998; Farina, Tacconelli et al. 1999; Yan, Wang et al. 2004), 
we hypothesized that overexpression of Mmp9 and Il4i1 in Nfkb2/p100-/- mice was caused by 
increased nuclear translocation of Nf-kb1 signaling complexes (p50/Rela, p50/Relb). On that 
condition other typical Nf-kb1 target genes ought to be up-regulated, too. 
3.5.1 Nf-kb1 target gene analysis 
To test this hypothesis, we performed quantitative RT-PCR for several Nf-kb1 target genes, 
namely Ikb (Haskill, Beg et al. 1991), Nfkb1 (Ten, Paya et al. 1992), Relb (Bren, Solan et al. 
2001), Tnf (Shakhov, Collart et al. 1990), Timp1 (Schreiber, Jenner et al. 2006), and A20 
(Krikos, Laherty et al. 1992) was performed in BMD macrophages of Nfkb2+/+, Nfkb+-/-, and 
Nfkb2-/- mice. 
 
We found that expression levels of target genes did not differ between Nfkb2 knockout mice 
and wildtype controls. Especially Ikb which works as direct inhibitory feedback molecule of 
Nf-kb1, thereby serving as indirect indicator of Nf-kb1 activation, showed no increase of 
expression level between Nfkb2+/+ and Nfkb2-/- macrophages. Moreover, in contrast to Mmp9 
expression, all investigated genes, except for Relb, were inducible by stimulation with LPS. 
Stimulated cells did not reveal any differences in expression levels of Nf-kb1 target genes 
either. In the case of Tnf, the Nfkb2 knockout led to reduced expression of this gene (Figure 
28). 
 
In summary, one might conclude, that Mmp9 gene expression regulation in macrophages is 
probably independent of classical Nf-kb1 signaling, as on the one hand, typical Nf-kb1 target 
genes remained unaffected by the Nfkb2 knockout, and on the other hand, stimulation of 
LPS had no effect on Mmp9 expression. 
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Figure 28. Nf-kb1 target gene analysis. RT-PCR of classical Nf-kb1 target genes in bone marrow- 
derived macrophages of Ldlr
-/-
 mice after stimulation with LIGHT (100ng/ml), LPS (1µg/ml), and 
Medium control for 8 h. Ba was used as housekeeping gene. Experiments were run in quadruplicates. 
Sample numbers are given in the columns. Values are given as mean + SEM. *** (P < 0.001); ** (P < 
0.01); *(P < 0.05). 
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3.5.2 Targeted knockdown of components of the Nf-kb1 signaling cascade with 
siRNA 
This was further confirmed by targeted disruption of components of the Nf-kb1 signaling 
complex: 
3.5.2.1 Rela knockdown 
In order to assess whether Rela containing Nf-kb complexes are important for Mmp9/Il4i1 
regulation, we performed Rela targeting siRNA experiments in RAW cells. 
 
First, we were able to demonstrate that, in accordance with our previous findings, the Nfkb2 
knockdown led to increased Mmp9 and Il4i1 expression in RAW cells (Figure 29). 
 
 
Figure 29. Nfkb2 knockdown experiments: mRNA expression of Nfkb2 (A), Mmp9 (B), and Il4i1 (C) 
after targeted knockdown of Nfkb2 mRNA. Ba was used as housekeeping gene. Experiments were 
run in quadruplicates. Values are given as mean + SEM (n=3). ** (P < 0.01). 
 
Down-regulation of Rela by siRNA, however, did not affect Mmp9 or Il4i1 transcription 
(Figure 30). Equally, the Rela knockdown was not able to abolish enhanced Mmp9 and Il4i1 
transcription caused by Nfkb2 siRNA (Figure 31). 
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Figure 30. Rela knockdown experiments: mRNA expression of Rela (A), Mmp9 (B), and Il4i1 (C) 
after targeted knockdown of Rela mRNA. Ba was used as housekeeping gene. Experiments were run 
in quadruplicates. Values are given as mean + SEM (n=3). *** (P < 0.001). 
 
 
Figure 31. Nfkb2/Rela knockdown experiments: mRNA expression of Nfkb2 (A), Rela (B), Mmp9 
(C), and Il4i1 (D) after targeted knockdown of Nfkb2 and Rela mRNA. Ba was used as housekeeping 
gene. Experiments were run in quadruplicates.Values are given as mean + SEM (n=3). *** (P < 
0.001); ** (P < 0.01). 
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3.5.2.2 Relb knockdown 
Another Nf-kb family member with transcriptional activity is represented by Relb. As given in 
Figure 32 knockdown of Relb did not affect Mmp9 or Il4i1 transcription and was not able to 
abolish enhanced Mmp9 and Il4i1 transcription caused by Nfkb2 siRNA (Figure 33) 
 
 
Figure 32. Relb knockdown experiments: mRNA expression of Relb (A), Mmp9 (B), and Il4i1 (C) 
after targeted knockdown of Relb mRNA. Ba was used as housekeeping gene. Experiments were run 
in quadruplicates. Values are given as mean + SEM (n=3). ** (P < 0.01). 
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Figure 33. Nfkb2/Relb knockdown experiments: mRNA expression of Nfkb2 (A), Relb (B), Mmp9 
(C), and Il4i1 (D) after targeted knockdown of Nfkb2 and Relb mRNA. Ba was used as housekeeping 
gene. Experiments were run in quadruplicates. Values are given as mean + SEM (n=3). *** (P < 
0.001); ** (P < 0.01). 
 
Together with our previous findings these data indicate that regulation of Mmp9 and Il4i1 
expression in murine macrophages, although working through a p100-dependent 
mechanism, is probably independent of Rela and Relb containing Nf-kb complexes and 
thereby Nf-kb1 signaling. 
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4 Discussion 
Existing evidence indicates that the Nf-kb transcription factor family plays a key role in the 
inflammatory response of cells involved in atherosclerotic lesion formation. The effect of the 
alternative Nf-kb2 pathway on atherogenesis has not been investigated until now. Indirect 
evidence was given by investigations from Mach and Schönbeck who found that treatment 
with antibodies against mouse Cd40 ligand (Cd40L) limited atherosclerosis in Ldlr-deficient 
mice (Mach, Schonbeck et al. 1998). Cd40L bind to Cd40, one of the best characterized 
alternative Nf-kb2 receptors (Coope, Atkinson et al. 2002). This implies atherosclerosis 
promoting abilities for the Nfkb2 pathway. However, Cd40 signals to both the classical and 
the alternative pathway. In 2004, Monaco suggests that Nf-kb1 but not Nf-kb2 is involved in 
the inflammatory response taking place in human atherosclerotic lesions. This was based on 
her finding that cells isolated from human atherosclerotic tissue showed activation of 
components of the classical Nf-kb1 pathway (p65, p50) but not of the alternative pathway 
(p52, Relb) (Monaco, Andreakos et al. 2004). 
 
The present thesis provides evidence for the first time that alternative Nf-kb2 is present in 
murine atherosclerotic lesions and has a protective effect on lesion development. 
Quantification of atherosclerotic lesion was performed on two atherosclerosis sensible 
backgrounds, the Apoe- and Ldlr- deficient background. Male and female Nfkb2-/- mice on 
the Apoe-/- background developed significantly larger lesion at the aortic root and the 
brachiocephalic artery. Consistent with former studies (Merat, Fruebis et al. 2000) lesion 
development in Ldlr-/- was less overt, but still we observed a trend to larger plaques in Nfkb2-/-
Ldlr-/- mice compared to Ldlr-/- controls. All mice were fed a low-fat semisynthetic diet for 16 
weeks. As atherosclerotic lesion development in Ldlr-/- mice is highly accelerated by high-fat, 
high-cholesterol diets (Ishibashi, Goldstein et al. 1994), we assumed that our feeding regime 
might also have contributed to less lesion development in Ldlr-/- mice. Elevated lesion burden 
in Nfkb2-/- mice was independent of plasma lipoproteins which did not differ between Nfkb2-/- 
mice and Apoe-/-/Ldlr-/- controls. 
 
Due to disturbed and oscillatory flows near arterial bifurcations and curvatures different 
segments of the vasculature display elevated susceptibility to atherosclerotic lesion formation 
(Cunningham and Gotlieb 2005). Expression analyses in defined vascular segments (AR, 
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BCA, AA, TA) revealed that Nfkb2 mRNA expression was highest at the brachiocephalic 
artery where oscillatory shear stress patterns occur. This was consistent with the strong 
effect of the Nfkb2 knockout on atherosclerotic lesion development in this segment of the 
vascular bed. We concluded that the presence of Nf-kb2 might be crucial for the innate 
immune responses taking place in atherosclerotic lesions. One of the key players in innate 
immunity is represented by monocytes, which have been recruited to the intima of activated 
endothelial cells. Monocytes differentiate into macrophages and express Tlrs which lead to 
activation of the Nf-kb transcription factor family. Nf-kb induces gene expression of target 
genes such as pro-inflammatory cytokines, chemokines, adhesion molecules, and proteases, 
initiating the chronic inflammatory response (Hansson and Hermansson 2011) (Figure 2). To 
date, no study has investigated the influence of the Nfkb2 knockout on macrophage gene 
expression. All “Nf-kb2 specific target genes” which have been identified so far are organic 
chemokines, critical for spleen organogenesis and maintenance of tissue-microarchitecture 
(Bonizzi, Bebien et al. 2004). In most cells, however, Nf-kb2 (p100/p52) is mostly present as 
cytoplasmatic p100 which was shown to act as inhibitor of classical Nf-kb1 activation (Basak, 
Kim et al. 2007). Thus, it is likely to assume that many genes are indirectly regulated by the 
alternative Nf-kb2 pathway. 
 
In order to find out how the Nfkb2 knockout influences inflammatory gene expression, we 
performed microarray experiments in macrophages from Nfkb2-/- mice and wildtype controls. 
Microarray experiments yield more than 1000 differentially expressed target genes with a P-
value < 0.01. Most differentially expressed was the gelatinase Mmp9. Mmp-9 belongs to a 
family of zinc-dependent endopeptidases capable of cleaving components of the ECM 
(Jones, Sane et al. 2003). They can be secreted by all cells present in the vascular wall but 
macrophages are particularly important (Newby and Johnson 2005). In particular Mmp-9 was 
found to promote atherosclerotic lesion formation in mice and human: Genetic analysis by 
Zhang (1999) showed that a polymorphism (-1562C-T) in the promoter region of the Mmp9 
gene has a functional effect on transcription and is associated with the severity of the 
atherosclerosis in patients with coronary artery disease (Zhang, Henney et al. 1999; Zhang, 
Ye et al. 1999). Luttun demonstrated in 2004, that Mmp9 but not Mmp12 deficiency protects 
mice against atherosclerosis in Apoe-deficient mice (Luttun, Lutgens et al. 2004). 
 
Differential Mmp9 expression could be confirmed by quantitative RT-PCR, revealing highly 
significant upregulation of Mmp9 in Nfkb2-/- macrophages. Notably, enhanced Mmp9 
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expression could not be further augmented by stimulation with LIGHT, a ligand for 
lymphotoxin beta receptor (Bodmer, Schneider et al. 2002), or LPS, which represent potent 
stimulators of the alternative Nf-kb2 and classical Nf-kb1 pathway, respectively (Mordmuller, 
Krappmann et al. 2003). This confirms data in human macrophages where upregulation of 
Mmp9 expression by LPS has also been found to be modest or absent (Welgus, Campbell et 
al. 1990; Saren, Welgus et al. 1996). Despite the important role of Mmp-9 in many 
physiological and disease-related processes, no evidence exists until now how the 
constitutive expression of Mmp9 in macrophages is regulated (Newby 2008). Our data 
provide strong evidence that the alternative Nf-kb2 pathway is crucial for constitutive Mmp9 
transcription in murine macrophages. 
 
Overexpression of Mmp9 was confirmed in parenchymatous organs, especially liver and 
spleen, but also in other tissues like lung and heart (data not shown). This is of particular 
importance for other Mmp-9- associated disorders like tumor invasion and angiogenesis (Yu 
and Stamenkovic 2000), heart failure and ventricular remodelling (Sundstrom, Evans et al. 
2004) and asthma (Kelly, Busse et al. 2000). 
 
Immunohistochemical characterization of atherosclerotic lesions in Nfkb2-/- mice revealed 
that overexpression of Mmp9 resulted in an inflammatory plaque phenotype with advanced, 
macrophage-rich lesions. This was consistent with increased gelantinolytic activity in serum 
of Nfkb2-deficient mice and enhanced plasminogen-induced Nfkb2-/- macrophage invasion 
across ECM in vitro. Overexpression of Mmp9 in Nfkb2-/- mice is thus likely to have 
contributed to increased inflammatory cell migration in the atheroma and thereby 
atherosclerotic lesion development (Figure 34). 
 
As mentioned above, Nf-kb2 (p100/p52) is mainly present as the Ikb-like precursor protein 
p100 in most cells. The Ikb-like function of p100 has been demonstrated for the inhibition of 
Relb and p50/Rela nuclear translocation (Solan, Miyoshi et al. 2002; Basak, Kim et al. 2007). 
We assumed that upregulation of inflammatory target genes (like Mmp9) in Nfkb2-/- mice was 
due to the lack of the inhibitory function of p100.  
Repetition of experiments in p100-/- macrophages revealed highly significant upregulation of 
Mmp9 in p100-/- mice. Similarly to our date from Nfkb2-/- macrophages, overexpression of 
Mmp9 could not be further augmented by stimulation with LIGHT or LPS.  
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These data provide strong evidence that constitutive expression of Mmp9 in murine 
macrophages is regulated by the Nf-kb2 precursor protein p100, establishing p100 as an 
important modulating factor in the inflammatory response of macrophages (Figure 34). 
 
 
Figure 34. Scheme of Mmp9 transcriptional regulation in murine macrophages. Stimulus induced 
Nfkb2 expression leads to formation of cytoplasmatic p100 dimers which normally inhibit expression of 
inflammatory target genes like Mmp9. In Nfkb2
-/-
 mice the lack of inhibitory p100 induces overexpres-
sion of Mmp9 through an unknown mechanism. Increased Mmp9 expression leads to enhanced 
atherosclerotic lesion development in Nfkb2
-/- 
mice. 
 
In 1993 Sato found that a functional p50/Rela binding element exists in the Mmp9 promoter, 
implying important functions for Nf-kb1 in Mmp9 transcription (Sato and Seiki 1993). In 1998 
Bond showed in primary cultures of human and rabbit fibroblasts that overexpression of Ikb, 
the endogenous inhibitor of Nf-kb1, completely inhibited Nf-kb1 binding and Mmp9 mRNA 
expression, demonstrating an absolute requirement for Nf-kb1 in Mmp9 gene regulation 
(Bond, Fabunmi et al. 1998). We thus hypothesized that overexpression of Mmp9 in Nfkb2-/-
/p100-/- mice might be due to enhanced activation of classical Nf-kb1 signaling in these mice. 
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Expression analysis of classical Nf-kb1 target genes in Nfkb2-/- macrophages revealed that 
expression levels of target genes did not differ between Nfkb2 knockout mice and wildtype 
controls. Especially Ikb which works as direct inhibitory feedback molecule of Nf-kb1, 
thereby serving as indirect indicator of Nfkb1 activation, showed no upregulation in Nfkb2-/- 
macrophages. Our findings suggest that it is not increased activity of Nf-kb1 (p50/Rela) 
signaling which accounts for enhanced Mmp9 expression. This was convincingly confirmed 
by gene pulldown experiments with targeted disruption of components of the Nf-kb signaling 
module. Neither knockdown of Rela nor Relb mRNA was able to abolish enhanced Mmp9 
transcription caused by Nfkb2 siRNA. 
 
In summary, we found that regulation of Mmp9 expression in murine macrophages works 
through a p100-dependent mechanism independently of Rela and Relb containing Nf-kb 
complexes. Further experiments will have to focus on the detailed mechanisms by which 
cytoplasmatic p100 regulates the transcriptional activity of the identified target genes. 
 
In addition to Mmp9, we identified Il4i1 as a highly significantly up-regulated target gene in 
Nfkb2-/- macrophages. Il4i1 is a leukocyte L-amino acid oxidase (LAAO) which has a 
preference for aromatic amino acid substrates, particularly phenylalanine, and was found to 
be located in lysosomes (Mason, Naidu et al. 2004). For several reasons Il4i1 is believed to 
play an important role in the immune system: It is induced as early response gene from Il-4, 
a key regulator of the immune response (Paul 1991), and it genetically maps to a region of 
autoimmune disease (Mason, Naidu et al. 2004). Cell culture experiments revealed that Il4i1 
inhibits T-cell proliferation through H2O2 production in vitro (Boulland, Marquet et al. 2007). 
Analogous to Mmp9, Il4i1 was described as Nf-kb1 target gene in various studies: Marquet et 
al. detected a requirement for Nf-kb1 complexes for expression of Il4i1 in human myeloid cell 
populations, human B lymphocytes and human embryonic kidney 293 cell lines, postulating 
Nf-kb1 as a key factor in Il4i1 expression (Marquet, Lasoudris et al. 2010). Sanjabi 
demonstrated in 2005 that Il4i1 transcription can be induced by Rela and c-Rel in a murine 
macrophage model (Sanjabi, Williams et al. 2005). 
 
We show here for the first time, that the alternative Nf-kb2 pathway, especially p100, plays 
an important role in Il4i1 mRNA expression. More specifically, Il4i1 expression was highly 
significantly up-regulated in macrophages of Nfkb2-/- and p100-/- mice, comparable to Mmp9. 
In contrast to Mmp9, however, Il4i1 was induced by stimulation with LPS. Moreover, Il4i1 
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mRNA expression was significantly reduced in spleens of Nfkb2-/- mice, indicating different 
regulatory mechanisms for Il4i1 expression in different cell types. Indeed Marquet found in 
2010 that different pathways exist for Il4i1 induction in human myeloid cells like monocytes, 
macrophages, and dendritic cells, compared to B-cells. While the former are sensitive to 
STAT1 activation by Ifn- the latter respond to Il-4 stimulation (Il-4/STAT6 axis) (Marquet, 
Lasoudris et al. 2010). This may be a possible explanation for diverging mRNA expression of 
Il4i1 in macrophages and spleens in our experiments. Most intriguingly, like Mmp9, 
upregulation of Il4i1 could not be abolished by transfection with Rela siRNA, challenging the 
fact that Il4i1 represents an Nf-kb1 target gene.  
 
Whether or not differential Il4i1 expression in Nfkb2-/- macrophages also contributed to 
enhanced lesion formation in these mice cannot be deduced from our experiments. However, 
immunohistochmistry revealed that Il4i1 expression is not restricted to lymphoid tissue but 
can be readily observed in atherosclerotic lesions, especially in plaque-associated adventitia. 
Regarding the Nfkb2-/- phenotype, however, an obvious conclusion could be that 
overexpression of Il4i1 might be partially responsible for the lack of follicular dendritic cell 
network in secondary lymphoid organs that had been described in Nfkb2-/- mice (Caamano, 
Rizzo et al. 1998; Franzoso, Carlson et al. 1998). The disturbed dendritic cell function leads 
to a loss of B-cell follicles and thereby an impaired antibody response. This conclusion is 
emphasized by the fact that Il4i1 is primarily expressed in secondary lymphoid organs and 
that highest Il4i1 enzyme levels can be found in mature dendritic cells. 
 
In summary, our findings demonstrate that the relevancy of the alternative Nf-kb2 pathway is 
not restricted to secondary lymphoid organs and adaptive immunity but has important 
functions in gene regulation of murine macrophages, especially for Mmp9 and Il4i1. We 
propose that upregulation of certain genes might have contributed to increased lesion 
formation in Nfkb2 knockout mice. Our data have substantial impact for understanding the 
Nf-kb signaling system, demonstrating for the first time the unique role of the alternative Nf-
kb2 pathway and especially p100 in gene regulation. 
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Introduction 
Atherosclerosis is a chronic disease of the arterial wall leading to the formation of 
atheromatous plaques in the inner lining of arteries. Atherosclerotic lesions begin with the 
recruitment of inflammatory cells (mainly macrophages) in the tunica intima. Subsequently 
lipoproteins enter the arterial wall and promote atherogenesis. SMC-derived extracellular 
matrix production leads to formation of complex lesions with fibrous caps. The stability of the 
fibrous cap depends mainly on the balance of ECM production and degradation by 
proteinases, particularly matrix metalloproteinases (Mmps). During the process of 
atherosclerotic lesion formation, plaque rupture and thrombosis can occur and cause acute 
vascular obliteration. 
 
Diseases of the cardiovascular system still represent the leading cause of death and loss of 
productive life years in western societies. Despite accelerated effort to understand the 
molecular mechanisms and big comprehensive studies, the pathogenesis of atherosclerotic 
lesion development is still not fully understood, which is why new therapy approaches are 
missing to this day. Particulary the impact of the immune system has been topic of intensive 
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research in the last few years, establishing a potential role for nuclear factor kappa B (Nf-kb) 
in atherogenesis. 
 
Nf-kb proteins comprise a family of structurally-related transcription factors that are involved 
in the control of a large number of normal cellular and organismal processes, such as 
immune and inflammatory responses, developmental processes, cellular growth, and 
apoptosis. Incorrect regulation of Nf-kb has been linked to cancer, inflammatory and 
autoimmune diseases, septic shock, asthma, neurodegenerative disease, and improper 
immune development. Among the Nf-kb family one can distinguish between two different 
pathways: the classical Nf-kb1 pathway with Rela/p50 as predominant transcription factor, 
and the alternative Nf-kb2 pathway represented by Relb/p52 dimers. Both p50 and p52 are 
generated from larger precursor proteins, namely p105 for the classical and p100 for the 
alternative pathway. Many bacterial products and stimulation of a wide variety of cell-surface 
receptors lead to activation of classical Nf-kb1 dimers and fairly rapid changes in cytokine 
expression. The distinctive feature of the alternative Nf-kb2 pathway is its dependence on 
p100 processing, which is tightly regulated and depends on a specific set of receptors. 
Accordingly, in most cell types Nf-kb2 is mainly represented by cytoplasmatic p100 due to 
lack of active processing of this precursor. 
 
Objective 
The clarification of the molecular mechanisms in atherosclerosis revealed that the cellular 
interactions are fundamentally not different from those in other chronic inflammatory disease. 
However, anti-inflammatory therapies did not have the anticipated effect and some even 
aggravated atherosclerotic events. Despite its unique position in inflammatory signaling the 
impact of the Nf-kb transcription factor family on atherogenesis is still not understood. 
Particularly the role of the alternative Nf-kb2 pathway has not been investigated until now. 
Since its discovery, the relevancy of Nf-kb2 has been linked to secondary lymphoid organ 
development and adaptive immunity because this is where activated Relb/p52 transcription 
factors can primarily be found. Recent studies, however, provide evidence that cytoplasmatic 
p100 has important regulatory functions, implicating a potential role for Nf-kb2 in 
atherogenesis.  
 
The aim of the present thesis was to establish the influence of the alternative Nf-kb2 pathway 
on atherogenesis in a mouse model. 
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In particular we wanted to clarify: 
1. If Nf-kb2 is present in the vasculature and especially atherosclerotic lesions. 
2. Whether the Nfkb2 knockout aggravates or reduces atherosclerotic lesion develop-
ment in mice. 
3. Which target genes are directly or indirectly regulated by the alternative Nf-kb2 
pathway. 
4. How differential target gene expression in Nfkb2 knockout mice affects athero-
genesis and plaque composition in these animals. 
 
Results 
1. Using quantitative RT-PCR, expression of Nfkb2 was detected in the circulatory system. 
Highest Nfkb2 expression was found in the brachiocephalic artery (BCA) where oscillatory 
shear stress patterns occur. Immunohistochemistry in frozen sections of the BCA of female 
Nfkb2+/+Apoe-/- mice revealed that Nf-kb2 (p100/p52) positive cells could be observed in the 
adventitia, the vessel wall, and the actual plaque. This finding indicates that Nf-kb2 is present 
in the vasculature and atherosclerotic lesions and that disturbed or oscillatory flows near 
arterial bifurcations lead to an upregulation of Nfkb2 expression. Thus, we concluded that 
expression of Nfkb2 in the BCA might be associated with the susceptibility to atherosclerotic 
lesion development in this segment of the vascular bed. 
 
2. To identify the influence of Nf-kb2 on atherosclerotic lesion formation, we generated Nfkb2 
knockout mice on two different atherosclerosis sensible backgrounds, the Apoe- and Ldlr-
deficient background. All mice were kept on a semisynthetic diet with 0.02% cholesterol and 
sacrificed at 20 weeks of age. Atherosclerotic lesion development was quantified at the 
brachiocephalic artery and the aortic root. We found that Nfkb2-/-Apoe-/- mice developed 
significantly more atherosclerosis than wildtype controls, indicating a protective effect of Nf-
kb2 on lesion development. The impact of Nfkb2 deficiency was most evident at the BCA, 
consistent with elevated Nfkb2 expression in this segment of the vascular bed. 
 
Although more than 400 Nf-kb specific target genes have been identified during the last 20 
years there is little knowledge about genes that are selectively regulated by the alternative 
Nf-kb pathway. In most cell types Nf-kb2 is mainly represented by cytoplasmatic p100 due to 
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a lack of active processing of this precursor. P100 contains ankyrin repeats and acts as an 
inhibitor of kappa b-like molecule. Thus we assumed that many genes are regulated 
indirectly by Nf-kb2. We hypothesized that the lack of the inhibitory function of p100 in Nfkb2 
knockout mice led to an upregulation of inflammatory genes thereby augmenting 
atherosclerotic lesion development in Nfkb2-deficient mice. 
 
3. To test this hypothesis we performed microarray experiments in bone marrow derived-
macrophages from Nfkb2 knockout mice and wildtype controls on the Apoe- and Ldlr- 
deficient background. We found over 1000 differentially expressed genes with a P-value < 
0.01. Matrix metalloproteinase 9 (Mmp9) (FC 16, Ldlr-/- background) and Interleukin 4 
induced protein 1 (Il4i1) (FC 11, Apoe-/- background) were most differentially expressed. 
Matrix metalloproteinases are a family of structurally related zinc endopeptidases which 
affect atherosclerotic plaque growth and stability by different mechanisms like monocyte 
infiltration, smooth muscle cell proliferation and migration, elastin degradation and 
angiogenesis. In particular Mmp-9 was also found to promote atherosclerotic lesion formation 
in mice and humans. Thus, overexpression of Mmp9 is likely to have contributed to 
increased atherosclerosis in Nfkb2-deficient mice. Il4i1 is a leukocyte L-amino acid oxidase 
which has a preference for aromatic amino acid substrates, and was found to be located in 
lysosomes. Studies suggest that Il4i1 mRNA expression is restricted to secondary lymphoid 
organs with highest levels in lymph nodes and spleen. 
 
Overexpression of Mmp9/Il4i1 was confirmed by quantitative RT-PCR. We found highly 
significant upregulation of Mmp9 and Il4i1 in Nfkb2-/- macrophages on both backgrounds. 
Together these data indicate that Nfkb2 deficiency induced upregulation of inflammatory 
genes in macrophages, especially Mmp9 and Il4i1. Further expression analyses in p100 
knockout mice confirmed the hypothesis that upregulation of Mmp9/Il4i1 in Nfkb2-/- mice was 
caused by the lack of the inhibitory precursor p100. Expression analyses in p100-/- 
macrophages showed similar results to those in Nfkb2-/- mice. Despite additional experiments 
with targeted disruption of components of the Nf-kb signaling system by siRNA, we were not 
able to identify the mechanism by which cytoplasmatic p100 controls Mmp9/Il4i1 transcription 
in murine macrophages. 
 
Further experiments addressing Mmp-9 activity and Nfkb2-/- macrophage properties in vitro 
confirmed that increased Mmp9 expression in Nfkb2-/- mice led to enhanced proteolytic 
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activity (serum zymography) and increased Nfkb2-/- macrophage migration across 
extracellular matrix in vitro. 
 
4. To test whether enhanced atherosclerotic lesion formation and differential Mmp9 
expression in Nfkb2-/- mice is also associated with a different plaque phenotype, we 
performed immunohistochemistry and a modified Stary classification of atherosclerotic 
plaques in the BCAs of female Nfkb2+/+Apoe-/- and Nfkb2-/-Apoe-/- mice. The analysis 
revealed that Nfkb2-/- mice suffered from major lesions which were highly positive for Cd68 
macrophages, smooth muscle cells and Mmp-9, indicating an inflammatory plaque 
phenotype. Staining patterns of Mmp-9 mirrored those of Cd68, suggesting enhanced Mmp-9 
production by resident macrophages. Lesion composition was tested by Oil Red O staining 
for lipids. In brief we found that Nfkb2-/- mice had significantly larger numbers of advanced 
lesions with complex fibro-proliferative plaques and sometimes necrotic cores compared to 
wildtype controls.  
In summary, these data indicate that overexpression of Mmp9 in Nfkb2-/- mice resulted in an 
inflammatory plaque phenotype with advanced, macrophage-rich lesions. Overexpression of 
Mmp9 in Nfkb2-/- mice is thus likely to have contributed to increased inflammatory cell 
migration in the atheroma and thereby atherosclerotic lesion development. 
 
Conclusion 
Despite accelerated effort to understand the molecular mechanisms of atherosclerotic lesion 
formation, new therapy approaches are still missing. Research work of the past 10 years has 
revealed that inflammatory processes play a key role in lesion development. The 
transcription factor family Nf-kb represents a central signaling component in the inflammatory 
response of cells. Our data provide clear evidence that the alternative Nf-kb2 pathway 
protects against atherosclerosis in mice. Moreover, we were able to demonstrate that Nf-kb2 
(p100/p52) has important functions in gene regulation of murine macrophages, especially for 
Mmp9 and Il4i1. We thereby demonstrated for the first time, that constitutive Mmp9 
expression in murine macrophages is probably independent of classical Nf-kb1 signaling but 
works through a p100-dependent mechanism. The biological significance of differential 
Mmp9 expression in Nfkb2-/- macrophages was confirmed by serum zymography and 
macrophage invasion assays and resulted in a different plaque phenotype with advanced, 
macrophage-rich, inflammatory lesions. Overexpression of Mmp9 in Nfkb2-/- macrophages is 
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thus likely to have contributed to enhanced atherosclerotic lesion development in these 
animals. 
 
These data establish Nf-kb2 (p100/p52) as an important modulator of inflammatory pathways 
which is crucial in atherosclerotic lesion development. A better understanding of the Nf-kb 
signaling system will possibly help us to comprehend how the inflammatory balance during 
atherosclerosis is orchestrated and may contribute to design more specific and efficient Nf-kb 
based therapies. 
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